胃癌临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT03801876 / NCI-2018-03378

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

AI 简述这是一项III期试验，比较质子治疗与光子放疗用于食管癌。在美国开展。

?

适用疾病: Stage I Esophageal Adenocarcinoma；Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: NRG Oncology

正在招募 Phase 3

NCI NCT04157985 / NCI-2020-02016

Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors

AI 简述这是一项III期试验，比较免疫治疗不同治疗时长用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 3

NCI NCT05677490 / NCI-2022-08569

mFOLFIRINOX versus mFOLFOX with or without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

AI 简述这是一项III期试验，比较mFOLFIRINOX与mFOLFOX联合或不联合Nivolumab用于晚期HER2阴性食管癌、胃食管结合部癌和胃癌。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 2, Phase 3

NCI NCT06203600 / NCI-2023-11064

Adding Nivolumab to Usual Treatment for People with Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

AI 简述这是一项II/III期试验，在晚期胃癌或食管癌中加用Nivolumab。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: SWOG

正在招募 Phase 3

NCI NCT06265285 / NCI-2024-00637

Comparison of In-Home versus In-Clinic Administration of Subcutaneous Nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

AI 简述这是一项III期试验，比较Nivolumab在家与在诊所给药用于多种癌症。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 2, Phase 3

NCI NCT06367972 / NCI-2024-03278

Local Consolidative Therapy to Extend the Efficacy of Systemic Therapy in Oligoprogressive Metastatic Cancer, EXTEND-OP Trial

AI 简述这是一项II/III期试验，研究局部巩固治疗联合系统治疗用于寡进展转移性癌症，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 3

NCI NCT07043400 / NCI-2025-07441

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项III期试验，比较替雷利珠单抗皮下注射与静脉输注联合化疗用于不可切除或转移性胃或胃食管结合部腺癌。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: BeOne Medicines

正在招募 Phase 3 药物

ClinicalTrials.gov NCT01917552

Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

AI 简述这是一项3期试验，比较卡培他滨辅助化疗与观察用于IB期胃癌术后。

?

适用疾病: Gastric Cancer
干预: capecitabine
地点: South Korea
申办方: Asan Medical Center

正在招募 Phase 3 药物

ClinicalTrials.gov NCT01935778

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

AI 简述这是一项3期试验，比较多西他赛/卡培他滨/奥沙利铂与卡培他滨/奥沙利铂用于IIIb和IV期胃癌辅助化疗。

?

适用疾病: Gastric Cancer, Adjuvant Chemotherapy, XO
干预: Docetaxel and capecitabine and oxaliplatin，capecitabine and oxaliplatin
地点: South Korea
申办方: Asan Medical Center

正在招募 Phase 3 手术/操作

ClinicalTrials.gov NCT03961373

Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer

AI 简述这是一项III期试验，比较D2与D2plus淋巴结清扫术用于局部晚期胃癌。在意大利开展。

?

适用疾病: Locally Advanced Gastric Cancer
干预: Gastrectomy with D2 lymphadenectomy，Gastrectomy with D2plus lymphadenectomy
地点: Italy
申办方: University of Siena

正在招募 Phase 3 药物

ClinicalTrials.gov NCT04447352

HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

AI 简述这是一项III期试验，研究HIPEC联合FLOT对比FLOT单用用于胃癌及胃食管结合部腺癌。

?

适用疾病: Gastric Cancer；Gastroesophageal Junction Adenocarcinoma
干预: 5-Fluorouracil，Leucovorin，Oxaliplatin，Docetaxel
地点: Germany
申办方: Krankenhaus Nordwest

正在招募 Phase 3 药物

ClinicalTrials.gov NCT04787354

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

AI 简述这是一项III期试验，在韩国研究Oxaliplatin在XELOX辅助化疗中的最佳持续时间用于胃癌。

?

适用疾病: Gastric Cancer
干预: Oxaliplatin，Capecitabine
地点: South Korea
申办方: Hallym University Medical Center

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05078047

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

AI 简述这是一项III期试验，比较标准免疫治疗与每3个月给药一次的方案用于多种癌症。

?

适用疾病: Lung Cancer Metastatic；Renal Cell Carcinoma；Head and Neck Cancer
干预: Reduced dose intensity of IO
地点: France
申办方: UNICANCER

正在招募 Phase 3 药物其他

ClinicalTrials.gov NCT05226169

Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)

AI 简述这是一项III期试验，在韩国研究Ferinject用于晚期胃癌患者的治疗。

?

适用疾病: Advanced Gastric Carcinoma
干预: Ferinject，Conservative management
地点: South Korea
申办方: Asan Medical Center

正在招募 Phase 3 联合产品

ClinicalTrials.gov NCT05303714

PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer

AI 简述这是一项3期试验，研究FOLFOX和PIPAC用于寡转移性腹膜胃癌。在意大利等地开展。

?

适用疾病: Oligometastatic Gastric Adenocarcinoma
干预: FOLFOX and PIPAC
地点: Italy
申办方: Azienda Ospedaliera Universitaria Integrata Verona

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT05482516 / NCI-2023-01487

Evaluating Novel Therapies in ctDNA Positive GI Cancers

AI 简述这是一项3期试验，评估Atezolizumab联合贝伐珠单抗用于ctDNA阳性胃肠癌，包括结肠、直肠、胃癌等，在美国开展。

?

适用疾病: Colon Adenocarcinoma；Rectal Adenocarcinoma；Gastric Adenocarcinoma
干预: Atezolizumab，Bevacizumab
地点: United States
申办方: Georgetown University

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT06028737

Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

AI 简述这是一项II/III期试验，研究FLOT方案化疗用于局部晚期胃癌和胃食管结合部癌。

?

适用疾病: Gastric Cancer；Stomach Cancer；GastroEsophageal Cancer
干预: Docetaxel，Oxaliplatin，Leucovorin，Fluorouracil
地点: Lithuania，Ukraine
申办方: Ukrainian Society of Clinical Oncology

正在招募 Phase 2, Phase 3 药物手术/操作

ClinicalTrials.gov NCT06232434

An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II

AI 简述这是一项II/III期试验，研究Prospidelong腹腔内用药用于播散性胃癌。在白俄罗斯开展。

?

适用疾病: Gastric Cancer With Peritoneal Dissemination
干预: Prospidelong，chemotherapy
地点: Belarus
申办方: Research Institute for Physical Chemical Problems of the Belarusian State University

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06346197

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

AI 简述这是一项III期试验，比较Balstilimab+Botensilimab与Folfox方案或XELOX用于MSI-H/dMMR局部晚期或转移性胃食管腺癌，在法国开展。

?

适用疾病: Gastric Cancer；MSI-H；Metastatic Cancer
干预: Balstilimab，Botensilimab，Folfox Protocol，XELOX
地点: France
申办方: Centre Leon Berard

正在招募 Phase 3 手术/操作

ClinicalTrials.gov NCT06608381

Comparison Partial Versus Total Omentectomy in Minimal Invasive Distal Gastrectomy for cT3/4a Gastric Cancer (KLASS-10)

AI 简述这是一项III期试验，比较部分与全网膜切除术用于cT3/4a胃癌，在韩国开展。

?

适用疾病: Gastric Cancer
干预: Arm I (Total omentectomy),，Arm II (Partial omentectomy)
地点: South Korea
申办方: Gangnam Severance Hospital

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06755554

Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer

AI 简述这是一项III期试验，研究吲哚菁绿对可切除胃癌淋巴结清扫范围的影响，在乌克兰开展。

?

适用疾病: Gastric Cancer Stage II；Gastric Cancer Stage III；Gastric Cancer
干预: Endoscopic injection of Indocyanine green
地点: Ukraine
申办方: Ukrainian Society of Clinical Oncology

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT06988475

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

AI 简述这是一项2/3期试验，研究Capmatinib用于MET失调的实体瘤和血液系统恶性肿瘤。在英国开展。

?

适用疾病: Solid Tumour；Haematological Malignancy；Malignant Neoplasm
干预: Capmatinib
地点: United Kingdom
申办方: Cancer Research UK

正在招募 Phase 2, Phase 3 药物手术/操作放疗

ClinicalTrials.gov NCT07000253

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma

AI 简述这是一项II/III期试验，在荷兰研究一线系统治疗后局部治疗时机用于寡转移食管或胃腺癌。

?

适用疾病: Esophageal Cancer；Gastric (Stomach) Cancer；Gastric Adenocarcinoma
干预: Chemotherapy，Targeted Systemic Therapy，Immunotherapy，Surgery
地点: Netherlands
申办方: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

正在招募 Phase 2, Phase 3 药物手术/操作

ClinicalTrials.gov / NCI NCT07001748 / NCI-2025-01831

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

AI 简述这是一项II/III期试验，研究腹腔内紫杉醇联合化疗用于胃癌伴腹膜转移。

?

适用疾病: Gastric Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma；Peritoneal Carcinomatosis
干预: Standard of Care Chemotherapy，Biospecimen Collection，Computed Tomography，Diagnostic Laparoscopy
地点: United States
申办方: ECOG-ACRIN Cancer Research Group

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07270991

Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma

AI 简述这是一项III期试验，在法国、德国等地比较曲氟尿苷替匹嘧啶联合呋喹替尼与单药用于转移性食管胃腺癌。

?

适用疾病: Metastatic Oesogastric Adenocarcinoma
干预: trifluridine/tipiracil，fruquintinib
地点: France，Germany
申办方: Federation Francophone de Cancerologie Digestive

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07304271

Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis

AI 简述这是一项III期试验，比较腹腔注射紫杉醇联合全身治疗与单独全身治疗用于胃癌腹膜转移，在意、荷、瑞典开展。

?

适用疾病: Gastric Cancer Peritoneal Metastases
干预: Intraperitoneal Paclitaxel，Standard systemic therapy
地点: Italy，Netherlands，Sweden
申办方: Magnus Nilsson

正在招募 Phase 2

NCI NCT01573468 / NCI-2012-00660

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

AI 简述这是一项II期试验，比较Tesetaxel联合卡培他滨与安慰剂联合卡培他滨用于胃癌或食管癌。

?

适用疾病: Recurrent Esophageal Cancer；Esophageal Adenocarcinoma；Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Genta Inc

正在招募 Phase 2

NCI NCT03412877 / NCI-2018-03627

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

AI 简述这是一项II期试验，研究基因工程T细胞用于多种转移性癌症。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer；Metastatic Digestive System Cancer
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 2

NCI NCT01174121 / NCI-2019-00142

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

AI 简述这是一项II期试验，研究肿瘤浸润淋巴细胞联合Pembrolizumab用于转移性癌症。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 2

NCI NCT03935893 / NCI-2019-06773

Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers

AI 简述这是一项II期试验，研究细胞疗法用于局部晚期、转移性或复发性实体瘤，在美国开展。

?

适用疾病: Recurrent Merkel Cell Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 2

NCI NCT04150640 / NCI-2019-07966

Fluorouracil, Oxaliplatin, and Liposomal Irinotecan with or without Trastuzumab, Nivolumab, and Pembrolizumab for the First Line Treatment of Advanced Esophageal or Gastric Adenocarcinoma

AI 简述这是一项II期试验，研究Nal-IRI和奥沙利铂联合曲妥珠单抗（用于HER2阳性）治疗晚期食管和胃腺癌。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

正在招募 Phase 2

NCI NCT04924075 / NCI-2021-07165

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

AI 简述这是一项II期试验，研究Belzutifan用于晚期嗜铬细胞瘤/副神经节瘤、胰腺神经内分泌肿瘤等，在美国开展。

?

适用疾病: Malignant Solid Tumor；Metastatic Paraganglioma；Locally Advanced Paraganglioma
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 1, Phase 2

NCI NCT04787042 / NCI-2021-09248

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

AI 简述这是一项I/II期试验，研究ST-067用于实体瘤、黑色素瘤、肾细胞癌和三阴性乳腺癌，在美国开展。

?

适用疾病: Recurrent Merkel Cell Cancer；Metastatic Urothelial Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Simcha IL-18, Inc.

正在招募 Phase 1, Phase 2

NCI NCT04723810 / NCI-2022-03872

Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care

AI 简述这是一项I/II期试验，研究吲哚青绿用于实体瘤术中成像，在美国开展。

?

适用疾病: Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Sarcoma
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05101070 / NCI-2022-06439

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究S-531011单药及联合免疫检查点抑制剂用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Shionogi

正在招募 Phase 2

NCI NCT05453825 / NCI-2022-07031

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

AI 简述这是一项II期试验，研究Navicixizumab单药或联合用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: OncXerna Theraputics, Inc.

正在招募 Phase 2

NCI NCT05651594 / NCI-2022-09209

Propranolol in Combination with Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项II期试验，普萘洛尔联合帕博利珠单抗和标准化疗用于不可切除局部晚期或转移性食管或胃食管结合部腺癌。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 2

NCI NCT05753306 / NCI-2023-00431

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Gastric Cancer with Limited Peritoneal Metastasis, ROBO-CHIP Study

AI 简述这是一项II期试验，在美国研究机器人肿瘤减灭术联合热腹腔化疗用于胃癌腹膜转移。

?

适用疾病: Gastric (Stomach) Adenocarcinoma；Metastatic Malignant Neoplasm to the Peritoneum；Gastroesophageal Junction Adenocarcinoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 1, Phase 2

NCI NCT05584670 / NCI-2023-00867

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，首次人体研究SAR445877用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Sanofi Aventis

正在招募 Phase 2

NCI NCT05969860 / NCI-2023-05420

At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls

AI 简述这是一项II期试验，比较在家与在医院进行癌症治疗用于晚期癌症患者。

?

适用疾病: Advanced Malignant Solid Tumor；Advanced Head and Neck Cancer；Advanced Melanoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 1, Phase 2

NCI NCT05934539 / NCI-2023-05619

ALG.APV-527 First-in-human Study

AI 简述这是一项I/II期试验，研究ALG.APV-527用于转移性尿路上皮癌及晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Aptevo Therapeutics

正在招募 Phase 2

NCI NCT06078709 / NCI-2023-07432

Preoperative Hypofractionated Radiotherapy with FOLFOX for the Treatment of Stage I-III Esophageal or Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项II期试验，研究术前的低分次放疗联合FOLFOX用于I-III期食管或胃食管结合部腺癌。

?

适用疾病: Stage I Esophageal Adenocarcinoma；Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 1, Phase 2

NCI NCT05902988 / NCI-2023-08591

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

AI 简述这是一项I/II期试验，研究VLS-1488用于晚期实体瘤，包括卵巢癌、肺癌、乳腺癌等，在美国开展。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Malignant Solid Tumor；Non-Small Cell Squamous Lung Cancer
干预: 未列出
地点: United States
申办方: Volastra Therapeutics, Inc.

正在招募 Phase 2

NCI NCT06123338 / NCI-2024-01388

Pembrolizumab with Trastuzumab and Chemotherapy for the Treatment Resectable HER2-Positive Gastric, Esophageal, and Gastroesophageal Junction Cancer

AI 简述这是一项II期试验，研究帕博利珠单抗联合曲妥珠单抗和化疗用于可切除HER2阳性胃食管结合部癌，在美国开展。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Stage IVA Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2

NCI NCT06628310 / NCI-2024-10331

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

AI 简述这是一项II期试验，研究ABBV-400联合氟尿嘧啶、亚叶酸钙和Budigalimab用于局部晚期不可切除或转移性胃、胃食管结合部或食管腺癌。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Abbvie

正在招募 Phase 2

NCI NCT06330064 / NCI-2025-00431

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

AI 简述这是一项II期试验，研究Ifinatamab deruxtecan用于复发或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Bladder Urothelial Cancer；Metastatic Malignant Solid Tumor；Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 1, Phase 2

NCI NCT06795412 / NCI-2025-01950

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

AI 简述这是一项1/2期试验，研究PYX-201联合帕博利珠单抗用于晚期实体瘤。在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Pyxis Oncology, Inc

正在招募 Phase 1, Phase 2

NCI NCT06730750 / NCI-2025-02617

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BMS-986490联合或不联合贝伐珠单抗用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1, Phase 2

NCI NCT06956690 / NCI-2025-04298

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

AI 简述这是一项I/II期试验，在美国和澳大利亚研究ENV-501用于HER3表达实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Hummingbird Bioscience

正在招募 Phase 2

NCI NCT07139951 / NCI-2025-05845

Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Paclitaxel for the Treatment of Patients with Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence, HORIZON Trial

AI 简述这是一项II期试验，研究腹腔热灌注化疗联合顺铂和紫杉醇用于高腹膜复发风险的胃癌及胃食管结合部腺癌。

?

适用疾病: Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 1, Phase 2

NCI NCT07070232 / NCI-2025-06009

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

AI 简述这是一项I/II期试验，研究BNT326联合BNT327用于晚期恶性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: BioNTech SE

正在招募 Phase 1, Phase 2

NCI NCT07124117 / NCI-2025-07305

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国研究OBI-902用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: OBI Pharma, Inc

正在招募 Phase 1, Phase 2

NCI NCT07197827 / NCI-2025-07559

A Study of YL242 in Subjects With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究YL242用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 1, Phase 2

NCI NCT07205718 / NCI-2025-08225

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

AI 简述这是一项I/II期试验，研究TAK-188用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage III Lip and Oral Cavity Cancer
干预: 未列出
地点: United States
申办方: Takeda

正在招募 Phase 2

NCI NCT06590454 / NCI-2026-01852

Pyrvinium for the Treatment of Gastric Intestinal Metaplasia in Patients Previously Treated for Helicobacter Pylori Infection, REVISE Trial

AI 简述这是一项II期试验，研究Pyrvinium用于治疗既往幽门螺杆菌感染患者的胃肠化生，在美国开展。

?

适用疾病: Helicobacter Pylori Infection；Gastric (Stomach) Cancer；Gastric Precancerous Condition
干预: 未列出
地点: United States
申办方: Duke University Medical Center

正在招募 Phase 2

NCI NCT06340711 / NCI-2026-02016

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

AI 简述这是一项II期试验，研究Suratadenoturev联合帕博利珠单抗用于食管胃腺癌，在美国开展。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: NYP/Weill Cornell Medical Center

正在招募 Phase 1, Phase 2

NCI NCT07287995 / NCI-2026-02678

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

AI 简述这是一项I/II期试验，研究ASP2998单用及联合标准疗法用于实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1, Phase 2

NCI NCT07436728 / NCI-2026-03048

A Study of TAK-505 in Adults With Solid Tumors

AI 简述这是一项I/II期试验，研究TAK-505用于晚期实体瘤，包括头颈癌、非小细胞肺癌等。在美国开展。

?

适用疾病: Metastatic Head and Neck Cancer；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Takeda

正在招募 Phase 1, Phase 2

NCI NCT07186842 / NCI-2026-03238

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

AI 简述这是一项I/II期试验，研究BNT329用于晚期实体瘤（表达CA19-9）。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: BioNTech SE

正在招募 Phase 1, Phase 2

NCI NCT07335497 / NCI-2026-03444

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究CR-001用于局部晚期或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Crescent Biopharma, Inc.

正在招募 Phase 2

NCI NCT07475286 / NCI-2026-04624

Combined Systemic and Intraperitoneal Chemotherapy for the Treatment of Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

AI 简述这是一项II期试验，研究全身联合腹腔化疗用于胃及胃食管连接处腹膜癌病。

?

适用疾病: Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage IV Gastric (Stomach) Cancer；Metastatic Gastroesophageal Junction Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT03161522 / NCI-2018-01202

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

AI 简述这是一项II期试验，研究化疗联合或不联合放疗或手术用于寡转移食管癌或胃癌，在美国开展。

?

适用疾病: Gastric Adenocarcinoma；Oligometastasis；Stage IV Esophageal Adenocarcinoma AJCC v7
干预: Capecitabine，Chemotherapy，Conventional Surgery，Fluorouracil
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03175224

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

AI 简述这是一项II期试验，研究APL-101用于c-Met外显子14跳跃突变的非小细胞肺癌和晚期实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Solid Tumors；Advanced Cancer；Renal Cancer
干预: APL-101 Oral Capsules
地点: United States，Australia，Canada，France 等 7 个
申办方: Apollomics Inc.

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT03190941

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

AI 简述这是一项I/II期试验，研究输注靶向KRAS G12V的T细胞用于HLA-A*11:01阳性的胰腺癌、胃癌等患者。

?

适用疾病: Pancreatic Cancer；Gastric Cancer；Gastrointestinal Cancer
干预: Cyclophosphamide，Fludarabine，Anti-KRAS G12V mTCR PBL，Aldesleukin
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 联合产品药物

ClinicalTrials.gov / NCI NCT03259867 / NCI-2017-01862

Combination of TATE and PD-1 Inhibitor in Liver Cancer

AI 简述这是一项II期试验，研究Nivolumab联合肝动脉栓塞用于肝癌和胃癌。

?

适用疾病: Hepatocellular Carcinoma；Gastric Cancer；BCLC Stage C Hepatocellular Cancer
干预: Nivolumab Injectable Product，Trans-arterial tirapazamine embolization
地点: United States
申办方: Teclison Ltd.

正在招募 Phase 1, Phase 2 联合产品药物

ClinicalTrials.gov / NCI NCT03526835 / NCI-2021-03548

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究双特异性抗体MCLA-158用于晚期实体瘤。在美国、比利时、法国、荷兰等开展。

?

适用疾病: Advanced/Metastatic Solid Tumors；Colorectal Cancer；Gastric Cancer
干预: MCLA-158，MCLA-158 + Pembrolizumab，MCLA-158 + FOLFIRI，MCLA-158 + FOLFOX
地点: United States，Belgium，France，Netherlands 等 2 个
申办方: Merus B.V.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03539822 / NCI-2019-00380

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

AI 简述这是一项I/II期试验，研究Cabozantinib联合Durvalumab加或不加Tremelimumab用于胃癌、食管腺癌等消化道肿瘤。

?

适用疾病: Gastric Cancer；Esophageal Adenocarcinoma；Hepatocellular Carcinoma
干预: Cabozantinib，Durvalumab，Tremelimumab
地点: United States
申办方: Anwaar Saeed

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03825861

Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer

AI 简述这是一项II期试验，研究新辅助FOLFIRINOX用于局部晚期胃癌。

?

适用疾病: Gastric Cancer
干预: FOLFIRINOX
地点: Brazil
申办方: Instituto do Cancer do Estado de São Paulo

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04018872

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

AI 简述这是一项II期试验，研究伊曲康唑用于食管癌。

?

适用疾病: Esophagus Adenocarcinoma；Esophagus Squamous Cell Carcinoma；Gastroesophageal Junction Adenocarcinoma
干预: Itraconazole
地点: United States
申办方: Dallas VA Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04069273 / NCI-2020-06409

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

AI 简述这是一项II期试验，研究派姆单抗联合雷莫西尤单抗和紫杉醇用于晚期胃食管腺癌。

?

适用疾病: Gastric Cancer；GastroEsophageal Cancer；Adenocarcinoma
干预: Pembrolizumab Monotherapy，Ramucirumab，Paclitaxel
地点: United States
申办方: Harry H Yoon

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04107077 / NCI-2019-08764

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

AI 简述这是一项II期试验，研究腹腔镜热灌注化疗用于晚期胃癌腹膜转移。

?

适用疾病: Gastric Cancer；Peritoneal Carcinomatosis；Stage IV Gastric (Stomach) Cancer
干预: Cisplatin，Mitomycin
地点: United States
申办方: University of Chicago

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04114136 / NCI-2020-11521

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

AI 简述这是一项II期试验，研究PD-1抑制剂联合二甲双胍、罗格列酮用于多种实体瘤。

?

适用疾病: Melanoma；NSCLC；Hepatocellular Carcinoma
干预: Nivolumab or Pembrolizumab (dependent upon approved indication)，Metformin，Rosiglitazone
地点: United States
申办方: Dan Zandberg

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04421820 / NCI-2021-14002

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

AI 简述这是一项I/II期试验，研究BOLD-100联合FOLFOX用于晚期实体瘤，在美国、加拿大、德国、爱尔兰等地开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Gastric Cancers
干预: BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)，BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
地点: United States，Canada，Germany，Ireland 等 3 个
申办方: Bold Therapeutics, Inc.

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04550494 / NCI-2020-06906

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

AI 简述这是一项II期试验，研究Talazoparib用于携带DNA修复变异的晚期癌症患者。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Castration-Resistant Prostate Carcinoma
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04592211

Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer

AI 简述这是一项I/II期试验，研究Pembrolizumab联合Olaparib用于晚期胃癌。

?

适用疾病: Gastric Cancer Stage IV
干预: olaparib+pembrolizumab+paclitaxel
地点: South Korea
申办方: Yonsei University

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT04656041

Folfox+Irinotecan+Chemort In Esophageal Cancer

AI 简述这是一项II期试验，研究FOLFOX/nal-IRI联合化疗和质子放疗用于食管胃结合部腺癌。

?

适用疾病: Gastroesophageal Junction Adenocarcinoma；Esophagogastric Cancer
干预: FOLFOX/ nal-IRI，Paclitaxel，Carboplatin，Proton Radiation Therapy
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04771520 / NCI-2021-00702

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

AI 简述这是一项II期试验，研究Avapritinib用于CKIT或PDGFRA突变阳性晚期实体瘤。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: Avapritinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04895709 / NCI-2021-06088

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BMS-986340单药或联合治疗用于晚期实体瘤，包括宫颈癌、肺癌等。

?

适用疾病: Cervical Cancer；Gastric/Gastroesophageal Junction Adenocarcinoma；Microsatellite Stable Colorectal Cancer
干预: BMS-986340，BMS-936558-01，Docetaxel，Pumitamig
地点: United States，Australia，Canada，Germany 等 4 个
申办方: Bristol-Myers Squibb

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05086692 / NCI-2022-02678

A Beta-only IL-2 ImmunoTherapY Study

AI 简述这是一项I/II期试验，研究MDNA11联合Pembrolizumab用于晚期实体瘤，在美、澳、加、爱等地开展。

?

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Clear Cell Renal Cell Carcinoma
干预: MDNA11，Pembrolizumab (KEYTRUDA®)
地点: United States，Australia，Canada，Ireland 等 3 个
申办方: Medicenna Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05177133

Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)

AI 简述这是一项II期试验，研究Retifanlimab联合Capecitabine和Oxaliplatin用于dMMR食管胃癌，在荷兰开展。

?

适用疾病: Gastric Adenocarcinoma；Esophageal Adenocarcinoma
干预: Capecitabine，Oxaliplatin，Retifanlimab
地点: Netherlands
申办方: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05183126

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

AI 简述这是一项IV期试验，研究基于骨骼肌面积的紫杉醇输注药代动力学，用于乳腺癌、转移性胃癌、食管癌患者，在美国开展。

?

适用疾病: Breast Cancer；Metastatic Gastric Cancer；Esophageal Cancer
干预: Paclitaxel，Paclitaxel
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05269381 / NCI-2022-01258

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究新抗原肽疫苗联合Pembrolizumab用于晚期实体瘤。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IIIA Breast Cancer AJCC v8；Anatomic Stage IIIB Breast Cancer AJCC v8
干预: Cyclophosphamide，Neoantigen Peptide Vaccine，Pembrolizumab，Sargramostim
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05332002 / NCI-2022-02448

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

AI 简述这是一项2期试验，研究sFOLFOXIRI用于晚期胃食管癌，在美国开展。

?

适用疾病: Gastro-Intestinal Cancer；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
地点: United States
申办方: Rutgers, The State University of New Jersey

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT05438459

GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites

AI 简述这是一项1/2期试验，在Japan开展，研究GAIA-102腹腔给药用于微卫星稳定的晚期胃癌和胰腺癌伴恶性腹水。

?

适用疾病: Gastric Cancer；Pancreatic Cancer
干预: Phase I part，Phase II part
地点: Japan
申办方: Kyushu University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05476796

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

AI 简述这是一项2期试验，研究奥沙利铂联合纳武利尤单抗及化疗用于虚弱晚期胃癌、食管癌或胃食管结合部癌，在法国开展。

?

适用疾病: Gastric Adenocarcinoma；Esophagus Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma
干预: Trifluridine/Tipiracil，Oxaliplatin，FOLFOX regimen，Nivolumab
地点: France
申办方: UNICANCER

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05482893 / NCI-2022-10638

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

AI 简述这是一项1/2期试验，研究Spevatamig单药或联合化疗用于晚期胃腺癌、胰腺癌等，在美国开展。

?

适用疾病: Gastric or Gastroesophageal Junction Adenocarcinoma；Pancreatic Ductal Adenocarcinoma；Biliary Tract Cancer (BTC)
干预: Spevatamig (PT886)，Paclitaxel，Gemcitabine，Abraxane
地点: United States
申办方: Phanes Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05563766

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

AI 简述这是一项II期试验，研究伊曲康唑用于可切除食管癌。

?

适用疾病: Esophageal Adenocarcinoma；Esophageal Squamous Cell Carcinoma；Gastroesophageal Junction Carcinoma
干预: Itraconazole
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05620628

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

AI 简述这是一项II期试验，研究Savolitinib联合Durvalumab用于MET扩增晚期胃癌。

?

适用疾病: Stomach Cancer, Adenocarcinoma
干预: Durvalumab，Savolitinib
地点: South Korea
申办方: Jeeyun Lee

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05640830

Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

AI 简述这是一项I/II期试验，研究Trastuzumab联合Bevacizumab和Paclitaxel用于HER2阳性晚期胃癌二线治疗，在韩国开展。

?

适用疾病: HER2-positive Advanced Gastric Cancer
干预: trastuzumab, bevacizumab with paclitaxel (triple combination)
地点: South Korea
申办方: Kangbuk Samsung Hospital

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT05733000

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

AI 简述这是一项2期试验，研究Devimistat联合羟氯喹和氟尿嘧啶或吉西他滨用于晚期难治性实体瘤。

?

适用疾病: Advanced Biliary Tract Carcinoma；Advanced Colorectal Carcinoma；Advanced Gastroesophageal Junction Adenocarcinoma
干预: Biospecimen Collection，Computed Tomography，Devimistat，Fluorouracil
地点: United States
申办方: Northwestern University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05771584

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer

AI 简述这是一项2期试验，研究治疗性癌症疫苗AST-301用于胃癌，在台湾开展。

?

适用疾病: Gastric Cancer
干预: AST-301，rhuGM-CSF
地点: Taiwan
申办方: Aston Sci. Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05894824

T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

AI 简述这是一项I/II期试验，研究T-Dxd联合Ramucirumab用于HER2低表达胃癌或胃食管结合部腺癌。

?

适用疾病: Gastric Cancer；Gastroesophageal Junction (GEJ) Cancer
干预: T-Dxd(Trastuzmab deruxtecan), Ramucirumab
地点: South Korea
申办方: Yonsei University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05927857

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

AI 简述这是一项I/II期试验，在台湾研究Ramucirumab、nal-IRI和Trifluridine/Tipiracil二线治疗转移性胃癌。

?

适用疾病: Metastatic Gastric Adenocarcinoma；Second Line；Chemotherapy
干预: nal-IRI /Experimental，Ramucirumab /Experimental，Trifluridine/Tipiracil /Experimental
地点: Taiwan
申办方: National Health Research Institutes, Taiwan

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05977998 / NCI-2023-05915

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

AI 简述这是一项II期试验，研究围手术期紫杉醇用于胃腺癌伴腹膜转移或腹腔细胞学阳性。

?

适用疾病: Gastric Adenocarcinoma；Carcinomatosis；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: Paclitaxel，Dexamethasone，Diphenhydramine，Famotidine
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06038578 / NCI-2023-09551

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

AI 简述这是一项II期试验，研究TRK-950联合Ramucirumab和Paclitaxel用于胃癌。

?

适用疾病: Gastric Adenocarcinoma；Gastric Cancer；Gastroesophageal Junction Adenocarcinoma
干预: TRK-950，Ramucirumab，Paclitaxel
地点: United States，Japan，South Korea
申办方: Toray Industries, Inc

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06047379 / NCI-2024-08760

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

AI 简述这是一项1/2期试验，研究NEO212用于星形细胞瘤、胶质母细胞瘤或脑转移瘤。在美国开展。

?

适用疾病: Diffuse Astrocytoma, IDH-Mutant；Glioblastoma, IDH-wildtype；Brain Metastases, Adult
干预: NEO212 Oral Capsule，Ipilimumab，Pembrolizumab，Nivolumab
地点: United States
申办方: Neonc Technologies, Inc.

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06055439 / NCI-2024-07692

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

AI 简述这是一项1/2期试验，研究CHM-2101 CAR-T细胞用于神经内分泌肿瘤、结直肠癌、胃癌等实体瘤。

?

适用疾病: Neuroendocrine Tumors；Colorectal Cancer；Gastric Cancer
干预: CHM-2101 CAR-T cells
地点: United States
申办方: Chimeric Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06059495

Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study

AI 简述这是一项2期试验，研究Dostarlimab用于dMMR/MSI-H局部胃癌的等待观察策略。

?

适用疾病: Adenocarcinoma - GEJ；Gastric Adenocarcinoma
干预: Dostarlimab
地点: France
申办方: GERCOR - Multidisciplinary Oncology Cooperative Group

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

AI 简述这是一项1/2期试验，研究MDX2001用于晚期实体瘤，包括胆管癌、乳腺癌等。

?

适用疾病: Biliary Tract Cancer；Breast Cancer；Cervical Cancer
干预: MDX2001
地点: United States
申办方: ModeX Therapeutics, An OPKO Health Company

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06250036

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

AI 简述这是一项II期试验，研究Zimberelimab单药或联合Domvanalimab用于可切除的dMMR胃癌或胃食管结合部癌，在英国开展。

?

适用疾病: Locally Advanced Gastric Adenocarcinoma；MSI-H/dMMR Gastric Cancer；MSI-H/dMMR Gastroesophageal-junction Cancer
干预: Single agent zimberelimab，Combination zimberelimab + domvanalimab
地点: United Kingdom
申办方: Royal Marsden NHS Foundation Trust

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT06253611

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

AI 简述这是一项II期试验，研究EXL01联合Nivolumab和FOLFOX用于PD-L1 CPS≥5转移性胃癌。在法国开展。

?

适用疾病: Gastric Cancer
干预: Nivolumab，FOLFOX regimen，EXL01
地点: France
申办方: GERCOR - Multidisciplinary Oncology Cooperative Group

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06253650

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease

AI 简述这是一项II期试验，研究Trastuzumab Deruxtecan用于HER2阳性胃癌微小残留病变。在意大利开展。

?

适用疾病: Gastric Cancer；HER2-positive Gastric Cancer
干预: Experimental，Control
地点: Italy
申办方: Gruppo Oncologico del Nord-Ovest

正在招募 Phase 2 联合产品药物手术/操作

ClinicalTrials.gov NCT06313801

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

AI 简述这是一项II期试验，研究多西他赛等化疗联合PIPAC用于胃癌，在俄罗斯开展。

?

适用疾病: Gastric Cancer
干预: Docetaxel，Oxaliplatin，Calcium folinate，Fluorouracil
地点: Russia
申办方: Nizhny Novgorod Regional Clinical Oncology Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06333314

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

AI 简述这是一项II期试验，研究Dostarlimab用于dMMR/MSI的局部晚期或转移性癌症。

?

适用疾病: Pancreatic Adenocarcinoma；Ampulla of Vater Carcinoma；Adrenocortical Carcinoma
干预: Dostarlimab，Chemotherapy
地点: France
申办方: UNICANCER

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06395519

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

AI 简述这是一项I/II期试验，研究PARG抑制剂ETX-19477用于晚期实体恶性肿瘤。在美国开展。

?

适用疾病: Advanced or Metastatic Solid Tumors；Breast Cancer；Ovarian Cancer
干预: ETX-19477
地点: United States
申办方: 858 Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06399757 / NCI-2024-04491

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究APL-5125用于晚期实体瘤。在美国开展。

?

适用疾病: Colorectal Cancer；Cholangiocarcinoma；Appendiceal Adenocarcinoma
干预: APL-5125
地点: United States
申办方: Apollo Therapeutics Ltd

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06422403

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

AI 简述这是一项II期试验，研究减少免疫检查点抑制剂给药频率用于晚期癌症。在新加坡开展。

?

适用疾病: Carcinoma, Hepatocellular；Gastric Adenocarcinoma；GastroEsophageal Cancer
干预: Extended Dosing Interval - A，Extended Dosing Interval - B，Extended Dosing Interval - C，Standard of Care - A
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06487221 / NCI-2024-04532

Avutometinib and Defactinib in Diffuse Gastric Cancer

AI 简述这是一项II期试验，研究Avutometinib和Defactinib用于弥漫性胃癌在美国开展。

?

适用疾病: Gastric Cancer；Stomach Cancer；Stage III Gastric (Stomach) Cancer
干预: Avutometinib，Defactinib
地点: United States
申办方: Ryan H. Moy, MD, PhD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06580002

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

AI 简述这是一项II期试验，研究利鲁唑用于癌症相关认知障碍。

?

适用疾病: Breast Cancer；Sarcoma；Gastric Cancer
干预: Riluzole，Placebo
地点: United States
申办方: University of California, Irvine

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06695845 / NCI-2025-02546

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

AI 简述这是一项2期试验，研究Zanidatamab用于HER2表达肿瘤，在美国、韩国、西班牙等地开展。

?

适用疾病: Breast Cancer；Gastric Cancer；Esophageal Cancer
干预: Zanidatamab
地点: United States，South Korea，Spain
申办方: Jazz Pharmaceuticals

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

AI 简述这是一项I/II期试验，研究[212Pb]Pb-PSV359治疗用于胰腺癌、胃癌、食管癌等实体瘤。在美国开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Gastric Cancer；Esophageal Cancer
干预: [203Pb]Pb-PSV359，[212Pb]Pb-PSV359
地点: United States
申办方: Perspective Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06732856

A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer

AI 简述这是一项Ib/II期试验，研究Zolbetuximab联合多西他赛、奥沙利铂和S-1新辅助治疗局部晚期胃癌。在韩国开展。

?

适用疾病: Stomach Neoplasm；Gastric (Stomach) Cancer
干预: zolbetuximab，Oxaliplatin，Docetaxel，S-1
地点: South Korea
申办方: Asan Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06846346

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

AI 简述这是一项II期试验，研究Ivonescimab联合化疗用于晚期胃或胃食管腺癌。

?

适用疾病: Metastatic Esophageal Adenocarcinoma；Advanced Esophageal Adenocarcinoma；Metastatic Gastric Adenocarcinoma
干预: Ivonescimab，FOLFOX regimen，Irinotecan，Paclitaxel
地点: France
申办方: UNICANCER

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06921837

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

AI 简述这是一项I/II期试验，首次研究BDC-4182单药用于晚期胃癌和胃食管癌。

?

适用疾病: Gastric Cancer Adenocarcinoma Metastatic；Gastroesophageal Adenocarcinoma
干预: BDC-4182
地点: Australia，South Korea，Taiwan
申办方: Bolt Biotherapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06943521 / NCI-2025-04636

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究MT-4561用于多种晚期实体瘤，在美国和日本开展。

?

适用疾病: Head and Neck Squamous Cell Carcinoma (HNSCC)；Non-small Cell Lung Cancer (NSCLC)；Esophageal Cancer
干预: MT-4561
地点: United States，Japan
申办方: Tanabe Pharma America, Inc.

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT06962137

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

AI 简述这是一项II期试验，在Belgium研究Zolbetuximab联合紫杉醇和雷莫芦单抗用于CLDN18.2阳性胃食管癌。

?

适用疾病: Gastric Cancer Adenocarcinoma Metastatic；Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
干预: zolbetuximab，Retrospective cohort, no intervention
地点: Belgium
申办方: Universitaire Ziekenhuizen KU Leuven

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07018570

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项II期试验，研究FLOT方案联合帕博利珠单抗和短程放疗用于局部晚期胃食管结合部腺癌。

?

适用疾病: Gastroesophageal Junction (GEJ) Adenocarcinoma
干预: Pembrolizumab，Docetaxel，Oxaliplatin，Levofolinate
地点: Japan
申办方: National Cancer Center Hospital East

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07070466 / NCI-2025-07695

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

AI 简述这是一项II期试验，研究Ivonescimab联合FOLFOX用于晚期HER2阴性胃食管腺癌。

?

适用疾病: Stomach Cancer Stage IV；Esophagus Cancer；Stomach Cancer
干预: Ivonescimab，5-Fluorouracil，Oxaliplatin，Leucovorin
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07115043 / NCI-2025-09704

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究AZD6750联合rilvegostomig用于多种晚期实体瘤。在美国、澳大利亚、日本、韩国等地开展。

?

适用疾病: Melanoma；Non-small Cell Lung Cancer；Squamous Cell Carcinoma (Skin)
干预: AZD6750，rilvegostomig
地点: United States，Australia，Japan，South Korea
申办方: AstraZeneca

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07133490

INTERACT Stomach-II

AI 简述这是一项II期试验，研究腹腔化疗用于胃癌腹膜转移。在荷兰开展。

?

适用疾病: Peritoneal Metastases From Gastric Cancer
干预: intraperitoneal chemotherapy
地点: Netherlands
申办方: Erasmus Medical Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07149090

Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

AI 简述这是一项1/2期试验，研究Lenvatinib联合Nivolumab和化疗用于转移性胃癌伴恶性腹水。

?

适用疾病: STOMACH NEOPLASM；Gastric Cancer；Gastric Cancer Adenocarcinoma Metastatic
干预: Lenvatinib
地点: South Korea
申办方: Asan Medical Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07151040

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

AI 简述这是一项I/II期试验，在法国、西班牙、英国等地研究TH9619用于晚期实体瘤。

?

适用疾病: Solid Tumor；Colorectal Cancer (CRC)；Squamous Cell Carcinoma of Head and Neck
干预: TH9619
地点: France，Spain，United Kingdom
申办方: One-carbon Therapeutics AB

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07176312

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

AI 简述这是一项II期试验，研究Zanidatamab联合Pembrolizumab和化疗用于HER2和PD-L1阳性转移性胃食管腺癌，在德国开展。

?

适用疾病: Gastroesophageal Adenocarcinoma；First Line Therapy；HER2 + Gastric Cancer
干预: Zanidatamab，Pembrolizumab，mFOLFOX
地点: Germany
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

正在招募 Phase 2 手术/操作

ClinicalTrials.gov NCT07178808

PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER

AI 简述这是一项II期试验，研究肿瘤细胞减灭术联合腹腔热灌注化疗用于胃腺癌，在美国开展。

?

适用疾病: Gastric Adenocarcinoma
干预: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
地点: United States
申办方: Banner Health

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07223424

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

AI 简述这是一项II期试验，研究患者对皮下与静脉注射免疫治疗的偏好。在美国开展。

?

适用疾病: Renal Cell Carcinoma；Non Small Cell Lung Cancer；Melanoma
干预: nivolumab，pembrolizumab
地点: United States
申办方: Diwakar Davar

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07262619

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

AI 简述这是一项I/II期试验，研究EIK1005联合Pembrolizumab用于晚期实体瘤包括MSI-H肿瘤。

?

适用疾病: Advanced Solid Tumors；MSI-H or dMMR Advanced Solid Tumors；MSI-H/dMMR Gastric Cancer
干预: EIK1005，pembrolizumab (KEYTRUDA® )
地点: United States，Australia，New Zealand
申办方: Eikon Therapeutics

正在招募 Phase 2 诊断检测手术/操作

ClinicalTrials.gov / NCI NCT07282912 / NCI-2026-03014

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

AI 简述这是一项II期试验，比较标准治疗联合或不联合序贯减瘤干预用于转移性前肠腺癌且ctDNA阴性患者，在美国开展。

?

适用疾病: Foregut Adenocarcinoma；Esophageal Adenocarcinoma；Gastroesophageal Adenocarcinoma
干预: Sequential cytoreductive intervention，Signatera Genome ultra-sensitive ctDNA blood test
地点: United States
申办方: Yale University

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07341737

SL-28 for Advanced Solid Tumours

AI 简述这是一项1/2期试验，研究SL-28用于多种晚期实体瘤（如头颈癌、胰腺癌、肺癌）。在澳大利亚开展。

?

适用疾病: Head & Neck Cancer；Pancreas Carcinoma；Pancreas Cancer, Metastatic
干预: SL-28，SL-28，SL-28
地点: Australia
申办方: Second Life Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07488676 / NCI-2026-04341

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

AI 简述这是一项I/II期试验，研究ASP546C用于胃食管癌、胰腺癌或其他实体瘤，在美国和日本开展。

?

适用疾病: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma；Pancreatic Adenocarcinoma；Metastatic Malignant Solid Tumor
干预: ASP546C
地点: United States，Japan
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07529808

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

AI 简述这是一项I/II期试验，研究BHB810用于晚期胃癌和胃食管结合部腺癌。

?

适用疾病: Gastric Cancer；Gastric Adenocarcinoma；Gastric (Stomach) Cancer
干预: BHB810
地点: United States
申办方: BigHat Biosciences, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07554521

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

AI 简述这是一项II期试验，研究替雷利珠单抗联合化疗用于晚期不可切除胃癌、胃食管腺癌或食管鳞癌的美国少数族裔患者，在美国开展。

?

适用疾病: Advanced Unresectable Gastric Adenocarcinoma；Esophageal Squamous Cell Carcinoma；Advanced Gastroesophageal Adenocarcinoma
干预: Tislelizumab，Capecitabine，5-fluorouracil (5-FU)，Oxaliplatin
地点: United States
申办方: BeOne Medicines

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07631000 / NCI-2026-04628

A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer

AI 简述这是一项II期试验，在美国研究Cadonilimab联合化疗用于胃癌或胃食管交界处癌。

?

适用疾病: Gastric Cancer；Gastroesophageal-junction Cancer；Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: Cadonilimab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05318794

Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer

AI 简述这是一项II期试验，研究新辅助全身和腹腔内化疗用于晚期胃癌伴腹膜转移。

?

适用疾病: Gastric Cancer；Peritoneal Metastases；Chemotherapy Effect
干预: Doxorubicin and Cisplatin
地点: United Kingdom
申办方: Imperial College London

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07101666

Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer

AI 简述这是一项II期试验，研究短程放疗联合新辅助化疗用于胃癌。

?

适用疾病: Gastric Cancer
干预: Short course radiation therapy，Standard of care neoadjuvant chemotherapy
地点: United States
申办方: Washington University School of Medicine

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07364422

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

AI 简述这是一项I/II期试验，研究JPI-547联合伊立替康作为三线及以上治疗用于复发或转移性胃癌，在韩国开展。

?

适用疾病: Gastric Cancer (GC)
干预: JPI-547，Irinotecan (drug)
地点: South Korea
申办方: Onconic Therapeutics Inc.

即将招募 Phase 4 手术/操作

ClinicalTrials.gov NCT07467174

RCT Comparing Reduced-port Robotic and Conventional Laparoscopic Subtotal Gastrectomy

AI 简述这是一项IV期试验，比较减端口机器人与传统腹腔镜用于胃癌手术，在韩国开展。

?

适用疾病: Gastric Cancer
干预: conventional laparoscopy gastrectomy group (Port > 3)，reduced-port robotic group (Port ≤ 3)
地点: South Korea
申办方: Yonsei University

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07509008

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

AI 简述这是一项I/II期试验，在United States研究腹腔内输注TROP2 CAR/IL-15 TGFBR2 KO NK细胞用于胃癌腹膜转移。

?

适用疾病: Gastric Cancer, Metastatic
干预: TGFBR2 KO CAR27/IL-15 NK cells，Rimiducid (AP1903)，Fludarabine，Cyclophosphamide
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07581405

GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer

AI 简述这是一项II期试验，研究奥氮平在胃癌新辅助化疗患者中的作用。

?

适用疾病: Gastric Adenocarcinoma；Gastric Cancer
干预: Neoadjuvant chemotherapy，Olanzapine
地点: United States
申办方: University of Illinois at Chicago

即将招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07583810 / NCI-2026-03180

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

AI 简述这是一项II期试验，研究Nemtabrutinib联合Rituximab用于边缘区淋巴瘤。在美国开展。

?

适用疾病: Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma；Gastric Mucosa-Associated Lymphoid Tissue Lymphoma；Marginal Zone Lymphoma
干预: Biopsy Procedure，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07625930

RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial

AI 简述这是一项II期试验，研究辛伐他汀联合FLOT方案用于胃食管腺癌。在加拿大等地开展。

?

适用疾病: Gastroesophageal Adenocarcinoma
干预: SOC neoadjuvant FLOT (or FLOT-D) + simvastatin，SOC neoadjuvant FLOT (or FLOT-D)
地点: Canada
申办方: McGill University Health Centre/Research Institute of the McGill University Health Centre

正在招募 Phase 1

NCI NCT03076372 / NCI-2017-01170

A Study Evaluating MM-310 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究MM-310用于多种晚期实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Prostate Adenocarcinoma；Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Merrimack Pharmaceuticals

正在招募 Phase 1

NCI NCT02675946 / NCI-2018-00241

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

AI 简述这是一项I期试验，研究CGX1321单用或联合Pembrolizumab或Encorafenib+Cetuximab用于晚期实体瘤和晚期胃肠道肿瘤。

?

适用疾病: Stage IIIA Esophageal Cancer；Stage IIIB Esophageal Cancer；Stage IIIC Esophageal Cancer
干预: 未列出
地点: United States
申办方: Curegenix Inc.

正在招募 Phase 1

NCI NCT03129139 / NCI-2018-00874

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究Minnelide胶囊单用或联合白蛋白紫杉醇用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Minneamrita Therapeutics LLC

正在招募 Phase 1

NCI NCT03715933 / NCI-2018-03556

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

AI 简述一项I期试验，研究INBRX-109联合伊立替康等用于晚期实体瘤包括肉瘤，在美国、法国等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Unresectable Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Inhibrx Biosciences, Inc

正在招募 Phase 1

NCI NCT03943004 / NCI-2019-04697

Trial of DFP-14927 in Advanced Solid Tumors

AI 简述这是一项I期试验，研究DFP-14927用于晚期实体瘤。

?

适用疾病: Refractory Malignant Solid Tumor；Refractory Pancreatic Carcinoma；Recurrent Gastroesophageal Junction Adenocarcinoma
干预: 未列出
地点: United States
申办方: Delta-Fly Pharma, Inc.

正在招募 Phase 1

NCI NCT03986606 / NCI-2019-05462

A Study of PSB205 in Subjects With Advanced Solid Tumors

AI 简述这是一项I期试验，研究PSB205用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

正在招募 Phase 1

NCI NCT04329494 / NCI-2020-01254

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients with Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

AI 简述这是一项I期试验，在美国开展，研究PIPAC用于卵巢癌、胃癌等的腹膜转移。

?

适用疾病: Stage IV Gastric (Stomach) Cancer；Stage IV Appendix Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT04429542 / NCI-2020-04796

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

AI 简述这是一项I期试验，研究BCA101单药及联合治疗用于EGFR驱动的晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Non-Small Cell Squamous Lung Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Bicara Therapeutics

正在招募 Phase 1

NCI NCT04450732 / NCI-2020-05876

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

AI 简述这是一项I期试验，研究GQ1001用于HER2阳性晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: GeneQuantum Healthcare (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT04902443 / NCI-2021-01289

Pomalidomide and Nivolumab for the Treatment of Virus-Associated Malignancies with or without HIV

AI 简述这是一项I期试验，研究Pomalidomide联合Nivolumab用于病毒相关恶性肿瘤，包括头颈癌、鼻咽癌。

?

适用疾病: Metastatic Head and Neck Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: NCI - Center for Cancer Research

正在招募 Phase 1

NCI NCT05238922 / NCI-2022-03370

Study of INCB123667 in Subjects With Advanced Solid Tumors

AI 简述这是一项I期试验，研究INCB123667用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Incyte Corporation

正在招募 Phase 1

NCI NCT05983432 / NCI-2023-10398

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

AI 简述这是一项I期试验，研究BL-B01D1用于转移性或不可切除非小细胞肺癌及其他实体瘤，在美国、法国等地开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: SystImmune Inc.

正在招募 Phase 1

NCI NCT06108050 / NCI-2024-01130

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究JZP898单药或联合Pembrolizumab用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Jazz Pharmaceuticals

正在招募 Phase 1

NCI NCT06240728 / NCI-2024-01335

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

AI 简述这是一项1期试验，研究NPX887用于表达B7-H7的实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: NextPoint Therapeutics, Inc.

正在招募 Phase 1

NCI NCT05957536 / NCI-2024-01363

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

AI 简述这是一项I期试验，研究D3L-001单药用于HER2阳性晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: D3 Bio (Wuxi) Co., Ltd

正在招募 Phase 1

NCI NCT06244485 / NCI-2024-04787

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

AI 简述这是一项I期试验，研究Valemetostat Tosylate联合DXd ADC用于实体瘤患者。

?

适用疾病: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 1

NCI NCT06384352 / NCI-2024-07039

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究YL211用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT06623396 / NCI-2024-08421

Mesothelin-Targeted CAR T-Cell Therapy for the Treatment of Patients with Mesothelin-Positive Recurrent or Metastatic Esophagogastric Cancer and Peritoneal Carcinomatosis

AI 简述这是一项I期试验，在美国研究靶向间皮素的CAR-T细胞疗法用于食管胃结合部癌。

?

适用疾病: Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Metastatic Gastroesophageal Junction Adenocarcinoma；Recurrent Gastroesophageal Junction Adenocarcinoma
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1

NCI NCT06675136 / NCI-2024-08883

Nab-Paclitaxel PIPAC in Combination with Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer with Peritoneal Metastases

AI 简述这是一项I期试验，研究Nab-Paclitaxel PIPAC联合紫杉醇和Ramucirumab用于伴有腹膜转移的胃癌。

?

适用疾病: Stage IVB Gastric (Stomach) Cancer；Metastatic Gastric Adenocarcinoma；Metastatic Malignant Neoplasm to the Peritoneum
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06475937 / NCI-2024-09195

A Study of DM001 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究DM001用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT06529822 / NCI-2025-00334

A Personalized Cancer Vaccine for the Treatment of Muscle-Invasive Bladder Cancer, Gastroesophageal Cancer, Melanoma, and Non-small Cell Lung Cancer in Patients with Molecular Residual Disease

AI 简述这是一项1期试验，研究个性化癌症疫苗联合Poly ICLC用于实体瘤分子残留病灶阳性患者，在美国开展。

?

适用疾病: Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Siteman Cancer Center at Washington University

正在招募 Phase 1

NCI NCT06710379 / NCI-2025-02183

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

AI 简述这是一项I期试验，研究ADRX-0405用于晚期实体瘤。在美国开展。

?

适用疾病: Stage III Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Adcentrx Therapeutics

正在招募 Phase 1

NCI NCT06752681 / NCI-2025-03245

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究DAY301用于局部晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；FIGO Stage III Ovarian Cancer；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Day One Biopharmaceuticals, Inc.

正在招募 Phase 1

NCI NCT06657144 / NCI-2025-04098

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究CHS-114（Tagmokitug）联合Toripalimab等用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Coherus Oncology, Inc.

正在招募 Phase 1

NCI NCT06756035 / NCI-2025-04725

CT-95 in Advanced Cancers Associated With Mesothelin Expression

AI 简述这是一项I期试验，研究CT-95用于间皮素表达的晚期实体瘤，包括卵巢癌、间皮瘤和胰腺癌。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Context Therapeutics Inc.

正在招募 Phase 1

NCI NCT05733689 / NCI-2025-04867

A Response-Guided Neoadjuvant Treatment Approach for Treating Stage Ib-III Stomach or Gastroesophageal Junction Cancer, RANT-GC Trial

AI 简述这是一项1期试验，研究响应指导的新辅助治疗用于IB-III期胃癌或胃食管结合部癌。

?

适用疾病: Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: UC Irvine Health/Chao Family Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT07015697 / NCI-2025-05451

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

AI 简述这是一项I期试验，研究皮下注射Trastuzumab Deruxtecan用于转移性实体瘤患者。

?

适用疾病: Metastatic Malignant Solid Tumor；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募阶段未标明

NCI NCT07132918 / NCI-2025-06177

The Cardiac Radiation Therapy Sparing for Thoracic Cancers, HEARTS Trial

AI 简述这是一项II期试验，研究MRgART或LINAC用于胸部肿瘤，包括非小细胞肺癌、食管癌等，在美国开展。

?

适用疾病: Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

正在招募 Phase 1

NCI NCT06959706 / NCI-2025-08169

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究TGW101用于晚期实体瘤，包括转移性及局部晚期实体瘤等，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: Tagworks Pharmaceuticals BV

正在招募 Phase 1

NCI NCT07197671 / NCI-2025-08356

Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer

AI 简述这是一项I期试验，研究Y-NM600联合免疫检查点抑制剂用于转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

正在招募 O

NCI NCT06824363 / NCI-2025-08761

Tremelimumab with Durvalumab to Increase Immune Cells in Patients with Resectable or Locally Advanced Unresectable MSI-Stable or pMMR Esophageal, Gastroesophageal Junction and Gastric Adenocarcinoma with ARID1A Mutations

AI 简述这是一项早期I期试验，研究Tremelimumab联合Durvalumab用于胃食管腺癌伴ARID1a突变，在美国开展。

?

适用疾病: Stage I Esophageal Adenocarcinoma；Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: UC Irvine Health/Chao Family Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT07213791 / NCI-2025-09175

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

AI 简述这是一项I期试验，在美国等地研究LY4337713用于FAP阳性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Eli Lilly and Company

正在招募 Phase 1

NCI NCT07141706 / NCI-2025-09675

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究DB-1317用于晚期/转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1

NCI NCT06809114 / NCI-2026-00164

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

AI 简述这是一项I期试验，研究AT03-65用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Axcynsis Therapeutics Pte Ltd

正在招募 Phase 1

NCI NCT07218003 / NCI-2026-00632

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

AI 简述这是一项I期试验，研究RNDO-564单药或联合Pembrolizumab用于Nectin-4阳性实体瘤，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Rondo Therapeutics

正在招募 Phase 1

NCI NCT07317505 / NCI-2026-01129

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究JMT108用于治疗晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Conjupro Bio-Pharmaceuticals Inc

正在招募 Phase 1

NCI NCT05458219 / NCI-2026-02256

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究IBI343用于局部晚期不可切除或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Innovent Biologics (Suzhou) Co. Ltd.

正在招募 Phase 1

NCI NCT07532902 / NCI-2026-03007

A Study of BMS-986504 with Standard-of-Care Therapy for the Treatment of Patients with Advanced, Metastatic or Unresectable Solid Tumor Cancer with MTAP Loss

AI 简述这是一项I期试验，研究BMS-986504联合标准疗法用于MTAP缺失的晚期实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Stage II Esophageal Squamous Cell Cancer；Stage III Esophageal Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1

NCI NCT05841563 / NCI-2026-03026

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

AI 简述这是一项I期试验，在美国开展，研究PM54用于晚期实体瘤患者。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: PharmaMar SA

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT02139605

"Phase III Randomized Trial Comparing D2 vs D3 Lymphadenectomy With Gastric Cancer Following Neoadjuvant Chemotherapy

AI 简述这是一项试验，比较D2与D3淋巴结清扫术用于新辅助化疗后的胃癌，在印度开展。

?

适用疾病: Gastric Cancer
干预: D3 Lymphadenectomy
地点: India
申办方: Tata Memorial Centre

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT03385018

Trial for Application of Laparoscopic Total Gastrectomy With Lymph Node Dissection for Gastric Cancer (KLASS-06)

AI 简述这是一项在韩国开展的试验，比较腹腔镜与开腹全胃切除加淋巴结清扫用于胃癌。

?

适用疾病: Gastric Cancer
干预: Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach，Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach
地点: South Korea
申办方: Yonsei University

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT03740256 / NCI-2021-01066

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

AI 简述这是一项I期试验，研究CAdVEC用于HER2阳性晚期实体瘤，在美国开展。

?

适用疾病: Bladder Cancer；Head and Neck Squamous Cell Carcinoma；Cancer of the Salivary Gland
干预: CAdVEC
地点: United States
申办方: Baylor College of Medicine

正在招募阶段未标明放疗

ClinicalTrials.gov NCT04097067

ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma

AI 简述这是一项非随机试验，研究20 Gy放疗用于惰性胃肠淋巴瘤。

?

适用疾病: Follicular Lymphoma (Gastric or Duodenal)；Marginal Zone Lymphoma (Gastric or Duodenal)
干预: Radiation Therapy
地点: Germany
申办方: University Hospital Muenster

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT04221893 / NCI-2019-08355

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

AI 简述这是一项试验，研究放射治疗用于转移性胃肠癌，包括食管癌、胃癌等。

?

适用疾病: Stage IV Esophageal Adenocarcinoma；Stage IV Esophageal Squamous Cell Carcinoma；Stage IV Gastric Cancer
干预: Radiation Therapy (RT)
地点: United States
申办方: University of California, San Francisco

正在招募 Phase 1 生物制剂联合产品

ClinicalTrials.gov / NCI NCT04282044 / NCI-2021-03252

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

AI 简述这是一项I期试验，研究CRX100单药或联合帕博利珠单抗用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Triple Negative Breast Cancer；Colorectal Cancer
干预: CRX100 suspension for infusion，Fludarabine，Cyclophosphamide
地点: United States
申办方: BioEclipse Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04361708 / NCI-2020-13964

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

AI 简述这是一项I期试验，研究伊立替康联合5-FU、亚叶酸、奥沙利铂和多西他赛用于胰腺癌或胃食管交界腺癌。

?

适用疾病: Pancreatic Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma；Adenocarcinoma
干预: Oxaliplatin，Docetaxel，Leucovorin，Irinotecan
地点: United States
申办方: University of Chicago

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT04368702 / NCI-2020-04571

CONFIRM: Magnetic Resonance Guided Radiation Therapy

AI 简述这是一项磁共振引导放射治疗的研究，用于多种癌症。

?

适用疾病: Gastric Cancer；Invasive Breast Cancer；in Situ Breast Cancer
干预: Viewray MRIdian® Linac
地点: United States
申办方: Brigham and Women's Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04389632 / NCI-2020-03931

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

AI 简述这是一项I期试验，研究Sigvotatug Vedotin用于晚期实体瘤，在美国、法国、韩国、西班牙等地开展。

?

适用疾病: Carcinoma, Non-Small Cell Lung；Squamous Cell Carcinoma of Head and Neck；HER2 Negative Breast Neoplasms
干预: sigvotatug vedotin，pembrolizumab，cisplatin，carboplatin
地点: United States，France，South Korea，Spain 等 3 个
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募阶段未标明放疗

ClinicalTrials.gov NCT04498767

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

AI 简述这是一项立体定向体部放疗用于罕见寡转移癌的试验。在比利时、法国等国开展。

?

适用疾病: Gynecologic Cancer；Skin Cancer；Head and Neck Cancer
干预: Stereotactic body radiotherapy，Palliative RT
地点: Belgium，France，Germany，Italy 等 3 个
申办方: European Organisation for Research and Treatment of Cancer - EORTC

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04511039 / NCI-2020-05678

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

AI 简述这是一项I期试验，研究Trifluridine/Tipiracil联合Talazoparib用于局部晚期或转移性结直肠癌或胃食管癌。

?

适用疾病: Advanced Malignant Solid Neoplasm；Clinical Stage III Gastroesophageal Junction Adenocarcinoma；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma
干预: Trifluridine and Tipiracil Hydrochloride，Talazoparib Tosylate
地点: United States
申办方: Roswell Park Cancer Institute

正在招募阶段未标明药物手术/操作

ClinicalTrials.gov NCT04595929

Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-

AI 简述这是一项试验，研究加压腹腔内气溶胶化疗用于T3-4期胃癌腹膜转移。

?

适用疾病: Peritoneal Carcinomatosis；Gastric Cancer
干预: Staging laparoscopy，5-Fluorouracil，Leucovorin，Oxaliplatin
地点: Russia
申办方: St. Petersburg State Pavlov Medical University

正在招募 Phase 1 药物其他放疗

ClinicalTrials.gov / NCI NCT04615013 / NCI-2020-05329

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

AI 简述这是一项1期试验，研究NBTXR3联合化疗和放疗用于食管癌，在美国开展。

?

适用疾病: Cervical Esophagus Adenocarcinoma；Clinical Stage II Esophageal Adenocarcinoma AJCC v8；Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8
干预: Capecitabine，Carboplatin，Docetaxel，Fluorouracil
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT04890171

Comparison of Endoscopic Resection and Surgery for Early Gastric Cancer With Undifferentiated Histological Type

AI 简述这是一项比较内镜切除与手术治疗早期未分化型胃癌的试验，在韩国开展。

?

适用疾病: Stomach Cancer；Undifferentiated Type；Expanded Indication of Endoscopic Resection
干预: Endoscopic submucosal dissection，Surgery
地点: South Korea
申办方: National Cancer Center, Korea

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04999761

AB122 Platform Study

AI 简述这是一项I期试验，研究AB122联合TAS-116、TAS-120、TAS-115用于晚期或转移性实体瘤，在日本开展。

?

适用疾病: Advanced or Metastatic Solid Tumor；Pancreatic Ductal Adenocarcinoma；Colorectal Cancer
干预: AB122，AB122，TAS-116，AB122
地点: Japan
申办方: Taiho Pharmaceutical Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05005403 / NCI-2025-01100

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AI 简述这是一项I期试验，研究Azirkitug单药或联合其他药物用于非小细胞肺癌等实体瘤，在美国、加拿大等地开展。

?

适用疾病: Non-Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Micro Satellite Stable Colorectal Cancer
干预: Azirkitug，Budigalimab，Bevacizumab，Telisotuzumab Adizutecan
地点: United States，Canada，Israel，Japan 等 2 个
申办方: AbbVie

正在招募 EARLY / Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05041153 / NCI-2021-09188

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

AI 简述这是一项早期I期试验，研究Pembrolizumab联合Lenvatinib用于晚期胃食管腺癌。

?

适用疾病: Advanced Gastric Adenocarcinoma；Advanced Gastroesophageal Junction Adenocarcinoma；Clinical Stage III Gastric Cancer AJCC v8
干预: Lenvatinib，Pembrolizumab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05107674 / NCI-2023-00784

A Study of NX-1607 in Adults With Advanced Malignancies

AI 简述这是一项I期试验，研究NX-1607用于晚期恶性肿瘤。

?

适用疾病: Ovarian Cancer, Epithelial；Gastric Cancer；GastroEsophageal Junction (GEJ) Cancer
干预: NX-1607，Paclitaxel
地点: United States，United Kingdom
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05187182 / NCI-2022-02312

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

AI 简述这是一项I期试验，研究CA-4948联合FOLFOX/PD-1抑制剂加或不加Trastuzumab用于晚期胃癌和食管癌。在美国开展。

?

适用疾病: Gastric Cancer；Esophageal Cancer；Stomach Cancer
干预: CA-4948，Nivolumab，Pembrolizumab，Trastuzumab
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05274048 / NCI-2022-05652

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

AI 简述这是一项I期试验，研究Neratinib联合Fam-Trastuzumab Deruxtecan用于晚期胃食管癌。

?

适用疾病: Gastric Cancer；Gastrointestinal Cancer；HER2 Gene Mutation
干预: Neratinib Pill，Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
地点: United States
申办方: Fox Chase Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05277766

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

AI 简述这是一项I期试验，研究腹腔内气溶胶纳米脂质体伊立替康用于胃肠道癌腹膜转移，在比利时开展。

?

适用疾病: Peritoneal Carcinomatosis；Peritoneal Metastases；Colorectal Cancer
干预: PIPAC with Nal-IRI
地点: Belgium
申办方: University Hospital, Ghent

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT05344339

Billroth-II Modified Versus Roux-en-Y After Distal Gastrectomy for Gastric Cancer

AI 简述这是一项对比Billroth-II改良与Roux-en-Y远端胃切除术用于胃癌的试验。

?

适用疾病: Gastric Cancer；Distal Gastrectomy
干预: Distal gastrectomy
地点: Vietnam
申办方: University Medical Center Ho Chi Minh City (UMC)

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05427487

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

AI 简述这是一项1期试验，研究瘤内注射IVX037用于晚期或转移性实体瘤。

?

适用疾病: Colorectal Cancer；Gastric Cancer；Ovarian Cancer
干预: IVX037，Sintilimab
地点: Australia
申办方: ImmVirx Pty Ltd

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05483491 / NCI-2022-07699

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

AI 简述这是一项I期试验，研究KK-LC-1 TCR-T细胞用于胃癌、乳腺癌、宫颈癌、肺癌等实体瘤。

?

适用疾病: Gastric Cancer；Breast Cancer；Cervical Cancer
干预: KK-LC-1 TCR-T cells，Aldesleukin
地点: United States
申办方: Christian Hinrichs

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT05561907

Enteral Anastomosis for the Treatment of Gastric Outlet Obstruction: A Randomized Controlled Study Comparing Endoscopic Versus Surgical Gastrojejunostomy

AI 简述这是一项随机对照试验，比较内镜与外科胃空肠吻合术用于胃出口梗阻。

?

适用疾病: Gastric Outlet Obstruction
干预: Surgical gastrojejunostomy (SGJ)，Endoscopic gastrojejunostomy (EGJ)
地点: United States
申办方: Northwell Health

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项1期试验，研究Enzelkitug单药或联合免疫检查点抑制剂用于晚期实体瘤。

?

适用疾病: Locally Advanced or Metastatic Solid Tumors；NSCLC；HNSCC
干预: Enzelkitug，Atezolizumab，Pembrolizumab
地点: United States，Australia，Belgium，Canada 等 6 个
申办方: Genentech, Inc.

正在招募 Phase 1 联合产品药物

ClinicalTrials.gov / NCI NCT05768932 / NCI-2023-02515

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项1期试验，研究BAL0891用于晚期实体瘤或复发/难治性急性髓系白血病，在美国、韩国等地开展。

?

适用疾病: Advanced Solid Tumor；TNBC - Triple-Negative Breast Cancer；Gastric Cancer
干预: BAL0891，Tislelizumab，Paclitaxel
地点: United States，South Korea
申办方: SillaJen, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05872295 / NCI-2026-00679

IKS014 in Advanced Solid Tumors That Express HER2

AI 简述这是一项I期试验，研究IKS014用于HER2阳性晚期实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Breast Cancer；Gastric Cancer；Gastroesophageal-junction Cancer
干预: IKS014
地点: United States，Australia，New Zealand，Singapore
申办方: Iksuda Therapeutics Ltd.

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT05986890

Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction

AI 简述这是一项比较Roux-en-Y Bypass与gastrojejunostomy用于恶性胃出口梗阻的试验，在美国开展。

?

适用疾病: Malignant Gastric Outlet Obstruction
干预: Roux-en-Y Bypass，gastrojejunostomy
地点: United States
申办方: Corewell Health West

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06105515

Laparoscopic and Endoscopic Collaborative Surgery as Rescue-treatment for Advanced Gastric Cancer

AI 简述这是一项研究腹腔镜和内镜联合手术用于晚期胃癌的试验，在瑞典开展。

?

适用疾病: Gastric Cancer
干预: Laparoscopic and Endoscopic Collaborative Surgery (LECS)
地点: Sweden
申办方: Region Stockholm

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06202105

Comparison of Laparoscopic and Open Total Gastrectomy for Locally Advanced Gastric Cancer

AI 简述这是一项比较腹腔镜与开腹全胃切除术用于局部进展期胃癌的试验，在越南开展。

?

适用疾病: Gastric Cancer
干预: Laparoscopic gastrectomy
地点: Vietnam
申办方: University Medical Center Ho Chi Minh City (UMC)

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06242470 / NCI-2024-04298

A Study of MGC026 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究MGC026用于晚期实体瘤患者，在美国、澳大利亚、英国等地开展。

?

适用疾病: Advanced Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MGC026 Dose Escalation，MGC026 Dose for Expansion
地点: United States，Australia，United Kingdom
申办方: MacroGenics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06253871

A Phase 1/1b Study of IAM1363 in HER2 Cancers

AI 简述这是一项I/Ib期试验，研究IAM1363用于HER2相关肿瘤，在美国、法国、爱尔兰、意大利等地开展。

?

适用疾病: HER2 Mutation-Related Tumors；HER2；HER2-positive Breast Cancer
干预: IAM1363
地点: United States，France，Ireland，Italy 等 4 个
申办方: Iambic Therapeutics, Inc

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06266299 / NCI-2024-08649

A Study of KK2269 in Adult Participants With Solid Tumors

AI 简述这是一项I期试验，研究KK2269用于晚期实体瘤，在美国和日本开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Gastric Adenocarcinoma
干预: KK2269，Docetaxel
地点: United States，Japan
申办方: Kyowa Kirin Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06293898 / NCI-2024-07363

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

AI 简述这是一项I期试验，研究BL-M07D1用于HER2表达的多种晚期实体瘤。

?

适用疾病: Endometrial Cancer；Cervical Cancer；Ovarian Cancer
干预: BL-M07D1
地点: United States
申办方: SystImmune Inc.

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06364410 / NCI-2024-02982

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

AI 简述这是一项I期试验，研究Trastuzumab Deruxtecan联合Azenosertib用于胃癌或其他实体瘤，在美国开展。

?

适用疾病: Clinical Stage III Gastric Cancer AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastric Cancer AJCC v8
干预: Azenosertib，Biopsy Procedure，Biospecimen Collection，Computed Tomography
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06414733

HER-2 B Cell Peptide Vaccine

AI 简述这是一项I期试验，在HER2阳性实体瘤中研究MVF-HER-2肽疫苗，在美国开展。

?

适用疾病: Metastatic Breast Cancer；Metastatic Gastrointestinal Carcinoma；HER2-positive Breast Cancer
干预: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720
地点: United States
申办方: Pravin T.P Kaumaya

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06586957 / NCI-2025-00731

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究NKT3964用于晚期/转移性实体瘤。在美国开展。

?

适用疾病: Solid Tumor；Advanced Solid Tumor；Solid Tumor, Adult
干预: NKT3964
地点: United States
申办方: NiKang Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06617169

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

AI 简述这是一项I期试验，研究MNPR-101-PCTA-177Lu用于实体瘤。

?

适用疾病: Solid Tumor, Adult；Bladder Cancer；Urothelial Carcinoma
干预: MNPR-101-PCTA-177Lu
地点: Australia
申办方: Monopar Therapeutics

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06668454

Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)

AI 简述这是一项试验，研究术前化疗免疫治疗后手术用于寡转移食管胃癌，在加拿大开展。

?

适用疾病: Esophageal Cancer；Gastric Cancer；Oligometastatic Disease
干预: Surgical resection followed by preoperative chemoimmunotherapy for oligometastatic esophagogastric cancer
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1 药物放疗

ClinicalTrials.gov NCT06673329

Brodalumab in the Treatment of Immune-Related Adverse Events

AI 简述这是一项I期试验，研究Brodalumab用于免疫相关不良事件，涵盖多种癌症。

?

适用疾病: Breast Cancer；Esophageal Cancer；Kidney Cancer
干预: Brodalumab，CT scan
地点: United States
申办方: Brian Henick, MD

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06690112

Pilot Study for High Output Drainage Removal After Gastrectomy

AI 简述这是一项试验，研究胃切除术后高输出量引流管移除，在韩国开展。

?

适用疾病: Gastric Cancer
干预: Arm I (Drainage tube removal)
地点: South Korea
申办方: Gangnam Severance Hospital

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06731998

Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery

AI 简述这是一项观察性研究，比较局部麻醉与腹腔镜腹横肌平面阻滞用于腹部癌症手术后疼痛控制。

?

适用疾病: Oncologic Surgery；Cancer；Cancer Surgery
干预: Local Anesthesia，Laparoscopic Transversus Abdominis Plane block
地点: United States
申办方: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06768463

Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer

AI 简述这是一项非随机试验，比较系统治疗后行减瘤性胃切除术与单独系统治疗用于有限转移性胃癌。在越南开展。

?

适用疾病: Metastatic Gastric Cancer；Gastric Cancer；Systemic Therapy
干预: Cytoreductive Gastrectomy
地点: Vietnam
申办方: University Medical Center Ho Chi Minh City (UMC)

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06778954

Ropivacaine-Poloxamer 407 Gel for Pain Control After Open Gastrectomy

AI 简述这是一项试验，比较两种给药方式用于胃癌开腹术后镇痛。

?

适用疾病: Gastric Cancer
干预: Arm I (Peritoneal application group)，Arm II (Subcutaneous injection group)
地点: South Korea
申办方: Gangnam Severance Hospital

正在招募 Phase 1 联合产品药物其他

ClinicalTrials.gov / NCI NCT06789172 / NCI-2025-08170

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

AI 简述这是一项I期试验，研究OKN4395联合帕博利珠单抗用于实体瘤，包括肉瘤、头颈癌、非小细胞肺癌。

?

适用疾病: Solid Tumours；Sarcoma；HNSCC
干预: OKN4395，Pembrolizumab，Fasting，Fed
地点: United States，Australia，United Kingdom
申办方: Epkin

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06839716

Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic Gastrectomy

AI 简述这是一项试验，在韩国比较罗哌卡因-泊洛沙姆407水凝胶与腹横肌平面阻滞用于胃癌术后疼痛管理。

?

适用疾病: Gastric Cancer
干预: Arm I (Ropivacaine-Poloxamer 407 hydrogel group)，Arm II (TAP block group)
地点: South Korea
申办方: Gangnam Severance Hospital

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06841484

Comparison of Full Robotic Instrumentation and Assistant-Controlled Laparoscopic Instrumentation in Robotic Distal Gastrectomy

AI 简述这是一项试验，比较全机器人器械与助手控制腹腔镜器械在机器人远端胃切除术中的使用。

?

适用疾病: Gastric Cancer
干预: Arm I (Assistant-Controlled Laparoscopic Instrumentation)，Arm II (Assistant-Controlled Laparoscopic Instrumentation)
地点: South Korea
申办方: Gangnam Severance Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06882746 / NCI-2025-03676

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

AI 简述这是一项I期试验，在美国研究BI 765049用于晚期结直肠癌、胃癌或胰腺癌。

?

适用疾病: Colorectal Carcinoma；Gastric Carcinoma；Pancreatic Ductal Adenocarcinoma
干预: BI 765049
地点: United States
申办方: Boehringer Ingelheim

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06910657

IDOV-Immune for Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDOV-Immune用于晚期实体瘤，包括结直肠癌、胰腺癌等。在美国和澳大利亚开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Melanoma
干预: IDOV-Immune (oncolytic vaccinia virus)
地点: United States，Australia
申办方: ViroMissile, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06974110

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究MOMA-341用于晚期或转移性实体瘤。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Endometrial Cancer
干预: MOMA-341，Irinotecan，Immunotherapy
地点: United States，Australia
申办方: MOMA Therapeutics

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06984952

Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy

AI 简述这是一项在韩国开展的试验，评估ERAS方案用于胃癌微创胃切除术后恢复。

?

适用疾病: Enhanced Recovery After Surgery；Gastrectomy for Gastric Cancer
干预: ERAS protocol
地点: South Korea
申办方: Seoul National University Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06999187 / NCI-2025-07429

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

AI 简述这是一项I期试验，研究DR-0202用于晚期复发难治性癌，在美国开展。

?

适用疾病: Triple Negative Breast Cancer；HER2-negative Breast Cancer；Non Small Cell Lung Cancer
干预: DR-0202
地点: United States
申办方: Dren Bio

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07001592

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

AI 简述这是一项I期试验，在美国研究瘤内注射vvDD-hIL2-2-RG-1用于转移性胃肠和腹膜肿瘤。

?

适用疾病: Gastric Neoplasms；Esophageal Cancer；Liver Cancer
干预: vvDD-hIL-2-RG-1
地点: United States
申办方: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07021066 / NCI-2025-07108

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

AI 简述这是一项I期试验，研究BL-M05D1用于晚期实体瘤，在美国开展。

?

适用疾病: Gastric Adenocarcinoma；Advanced Pancreatic Ductal Adenocarcinoma；Esophageal Adenocarcinoma
干预: BL-M05D1
地点: United States
申办方: SystImmune Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07059299

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

AI 简述这是一项I期试验，研究替雷利珠单抗联合FLOT方案用于可切除食管胃腺癌，在德国开展。

?

适用疾病: Esophagogastric Junction Adenocarcinoma；Gastric Adenocarcinoma；Esophageal Adenocarcinoma
干预: Tislelizumab，FLOT Chemotherapy
地点: Germany
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07090499

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

AI 简述这是一项I期试验，研究PF-08046876用于晚期实体瘤，在美国、加拿大等地开展。

?

适用疾病: Advanced/Metastatic Solid Tumors；Bladder Cancer；Urothelial Carcinoma
干预: PF-08046876
地点: United States，Canada，Puerto Rico，Spain 等 1 个
申办方: Pfizer

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT07161479

Argon Plasma Coagulation Versus Endoscopic Mucosal Resection for Gastric Adenoma (CLER-GA)

AI 简述这是一项试验，在韩国比较氩离子凝固术与内镜下黏膜切除术用于胃腺瘤。

?

适用疾病: Gastric Adenoma；Stomach Neoplasms；Precancerous Conditions
干预: Argon Plasma Coagulation (APC)，Endoscopic Mucosal Resection (EMR)
地点: South Korea
申办方: Samsung Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07182149 / NCI-2026-01556

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究NRM-823用于晚期难治性实体瘤。

?

适用疾病: HNSCC；ESCC；Esophageal Adenocarcinoma
干预: NRM-823
地点: United States
申办方: Normunity AccelCo, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07227168 / NCI-2026-01753

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

AI 简述这是一项I期试验，研究STRO-004联合Pembrolizumab用于难治性/复发性转移性实体瘤，在美国开展。

?

适用疾病: Head and Neck Squamous Cell Carcinoma HNSCC；Non-Small Cell Lung Cancer NSCLC；Esophageal Cancer
干预: STRO-004，Pembrolizumab
地点: United States
申办方: Sutro Biopharma, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07277413 / NCI-2026-03872

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDE892单药或联合IDE397用于MTAP缺失的晚期实体瘤，在美国开展。

?

适用疾病: NSCLC Adenocarcinoma；Gastroesophageal Cancer (GC)；Gastric Adenocarcinoma
干预: IDE892，IDE397
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07284186

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究PLX-61639用于局部晚期或转移性实体瘤，包括食管鳞癌、胃腺癌等。

?

适用疾病: Esophageal Squamous Cell Carcinoma；Gastric Adenocarcinoma；Gastric Squamous Cell Carcinoma
干预: PLX-61639
地点: United States
申办方: Plexium, Inc.

正在招募 Phase 1 联合产品药物

ClinicalTrials.gov NCT07358806

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究OCT-598用于晚期实体瘤，在韩国开展。

?

适用疾病: Solid Tumor；Breast Cancer；Head and Neck Cancer
干预: OCT-598，Docetaxel
地点: South Korea
申办方: Oscotec Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07454642

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

AI 简述这是一项I期试验，研究AVA6103用于局部晚期或转移性实体瘤。

?

适用疾病: Vulvar Adenocarcinoma；PDAC - Pancreatic Ductal Adenocarcinoma；Gastric Adenocarcinoma
干预: AVA6103
地点: United States
申办方: Avacta Life Sciences Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07481357

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

AI 简述这是一项I/IIa期试验，研究DA-3501用于晚期胃/胃食管结合部腺癌和胰腺癌。

?

适用疾病: Gastric (Stomach) Cancer；GastroEsophageal Cancer；Pancreatic Ductal Adenocarcinoma (mPDAC)
干预: DA-3501
地点: South Korea
申办方: Dong-A ST Co., Ltd.

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT07482566

Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer

AI 简述这是一项研究，比较近端胃切除与全胃切除用于局部晚期Siewert II-III型胃食管结合部癌。

?

适用疾病: Gastroesophageal Junction Cancer；Stomach Neoplasms；Esophageal Neoplasms
干预: Proximal Gastrectomy，Total Gastrectomy
地点: Turkey (Türkiye)
申办方: Nurettin Şahin

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07517198

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

AI 简述这是一项I期试验，确定EXS74539用于多种实体瘤的剂量。在美国开展。

?

适用疾病: Solid Tumor；Small Cell Lung Cancer (SCLC)；High Grade Neuroendocrine Cancer
干预: EXS74539
地点: United States
申办方: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07544589 / NCI-2026-03246

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

AI 简述这是一项I期试验，在美国评估DISP-10用于晚期胃肠道癌症。

?

适用疾病: Colorectal Cancer；Gastric Adenocarcinoma；Esophageal Adenocarcinoma
干预: DISP-10
地点: United States
申办方: Dispatch Biotherapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07578571

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

AI 简述这是一项I期试验，在美国研究IM-1617用于多种晚期实体瘤。

?

适用疾病: Colorectal Cancer；Non-Small Cell Lung Cancer；Breast Cancer
干预: IM-1617
地点: United States
申办方: Immunome, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07593820

A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.

AI 简述这是一项I期试验，在西班牙开展，评估p95HER2.CAR-TECH2Me T细胞用于晚期胃癌、乳腺癌和子宫内膜癌。

?

适用疾病: Metastatic Gastric Cancer；Metastatic Breast Cancer；Endometrial Cancer Metastatic
干预: p95HER2.CAR-TECH2Me
地点: Spain
申办方: Vall d'Hebron Institute of Oncology

正在招募阶段未标明放疗

ClinicalTrials.gov NCT07607119

PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

AI 简述这是一项试验，研究PULSAR联合免疫治疗用于不可切除的局部晚期胃癌，在韩国开展。

?

适用疾病: Gastric Adenocarcinoma；Stomach Neoplasms；Locally Advanced Gastric Cancer
干预: PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy)，PULSAR
地点: South Korea
申办方: Samsung Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07646106

THE-0504 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究THE-0504用于多种实体瘤，在意大利开展。

?

适用疾病: Small Cell Lung Cancer (SCLC)；Colorectal Carcinoma (CRC)；Gastric Cancer (GC)
干预: THE-0504
地点: Italy
申办方: Thena Biotech S.r.l.

正在招募 Phase 1 诊断检测药物

ClinicalTrials.gov NCT07660055

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究[177Lu]Lu-DWJ155和[68Ga]Ga-DWJ155用于多种实体瘤，在澳大利亚、加拿大、日本等地开展。

?

适用疾病: Breast Cancer；Non-small Cell Lung Cancer (NSCLC)；Gastric/Gastroesophageal Junction (GEJ) Cancer
干预: [68Ga]Ga-DWJ155，[177Lu]Lu-DWJ155
地点: Australia，Canada，Japan
申办方: Novartis Pharmaceuticals

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT05180864

Omentum Preservation Versus Complete Omentectomy in Gastrectomy for Gastric Cancer

AI 简述这是一项试验，研究保留网膜与全网膜切除在胃癌胃切除术中的应用，在德国、意大利、荷兰、英国等地开展。

?

适用疾病: Stomach Neoplasm
干预: Gastrectomy
地点: Germany，Italy，Netherlands，United Kingdom
申办方: Amsterdam UMC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05184803

A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

AI 简述这是一项II期试验，研究新辅助多西他赛、奥沙利铂、S-1用于不可切除局部晚期或仅淋巴结远处转移的胃癌患者，在韩国开展。

?

适用疾病: Stomach Neoplasm
干预: Docetaxel injection, oxaliplatin, S-1
地点: South Korea
申办方: Asan Medical Center

正在招募阶段未标明放疗

ClinicalTrials.gov NCT05370144

A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项试验，研究低分次放疗联合新辅助放化疗用于食管癌和胃食管交界处腺癌，在加拿大开展。

?

适用疾病: Esophageal Cancer
干预: Hypofractionated radiotherapy
地点: Canada
申办方: AHS Cancer Control Alberta

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06085755

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

AI 简述这是一项早期试验，研究Trastuzumab deruxtecan与Afatinib联合用于HER2低表达晚期胃癌。

?

适用疾病: Stomach Neoplasm
干预: Trastuzumab deruxtecan，Afatinib
地点: South Korea
申办方: Jeeyun Lee

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06161818

Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction

AI 简述这是一项II期试验，研究FLOT-CROSS方案用于淋巴结阳性食管腺癌。

?

适用疾病: Esophageal Cancer；Adenocarcinoma of the Esophagus
干预: FLOT-CROSS or CROSS-FLOT
地点: Netherlands
申办方: Erasmus Medical Center

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06627634

Radical Surgery for Advanced Gastric- or GEJ-cancer With Oligometastatic Dissmination to the Liver

AI 简述这是一项试验，研究根治性手术用于晚期胃癌或胃食管结合部癌伴肝寡转移。

?

适用疾病: Survival
干预: Metastatectomia and standard treatment for resectable disease.
地点: Denmark
申办方: Aarhus University Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06630130

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

AI 简述这是一项II期试验，研究Trastuzumab deruxtecan、Rilvegostomig等用于局部晚期不可切除胃癌的围手术期治疗，在韩国开展。

?

适用疾病: Stomach Neoplasms
干预: Trastuzumab deruxtecan，Capecitabine，Rilvegostomig，Durvalumab
地点: South Korea
申办方: Jeeyun Lee

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06663319 / NCI-2025-00139

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

AI 简述这是一项I期试验，研究JNJ-89402638用于转移性结直肠癌和胃癌。

?

适用疾病: Colorectal Neoplasms；Gastrointestinal Neoplasms；Stage III Colorectal (Colon or Rectal) Cancer
干预: JNJ-89402638，Bevacizumab，FOLFOX，FOLFIRI
地点: United States，South Korea，Spain
申办方: Janssen Research & Development, LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07072728

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

AI 简述这是一项II期试验，研究Psilocybin therapy用于癌症伴适应障碍患者，在澳大利亚开展。

?

适用疾病: Adjustment Disorder；Adjustment Disorder With Anxious Mood；Cancer
干预: Psilocybin therapy
地点: Australia
申办方: Psyence Australia Pty Ltd

暂时不招募 Phase 2, Phase 3

NCI NCT03604991 / NCI-2018-01575

Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

AI 简述这是一项II/III期试验，研究Nivolumab联合Ipilimumab用于可切除食管或胃食管交界处腺癌。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Stage IVA Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: ECOG-ACRIN Cancer Research Group

即将招募 Phase 2, Phase 3 药物手术/操作

ClinicalTrials.gov NCT04677673

Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients

AI 简述这是一项II/III期试验，比较新辅助化疗后手术与直接手术用于老年胃癌患者。

?

适用疾病: Gastric Cancer；Chemotherapy Effect；Elderly Patients
干预: Chemotherapy，Curative gastrectomy
地点: 未列出
申办方: BIRENDRA KUMAR SAH

即将招募 Phase 3 联合产品药物

ClinicalTrials.gov NCT05230771

Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer

AI 简述这是一项III期试验，比较转化治疗后姑息手术与维持化疗用于转移性胃癌。

?

适用疾病: Metastatic Gastric Cancer；Surgery；Chemotherapy
干预: Palliative surgery after translational therapy，Chemotheraoy along
地点: 未列出
申办方: Fujian Medical University

即将招募 Phase 3 联合产品

ClinicalTrials.gov NCT05270824

Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma

AI 简述这是一项III期试验，比较新辅助免疫治疗与新辅助化疗用于晚期胃腺癌。

?

适用疾病: Advanced Gastric Carcinoma；CD8+ Tumor Infiltrating Lymphocytes；Neoadjuvant Immunotherapy
干预: radical surgery after neoadjuvant immunotherapy，radical surgery after neoadjuvant chemotherapy
地点: 未列出
申办方: Fujian Medical University

即将招募 Phase 2, Phase 3 联合产品

ClinicalTrials.gov NCT05300945

HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy

AI 简述这是一项2/3期试验，研究HIPEC用于晚期胃癌伴腹膜转移患者新辅助化疗后。

?

适用疾病: Gastric Cancer；Peritoneal Metastases
干预: HIPEC
地点: 未列出
申办方: Zhixin Cao

即将招募 Phase 3 药物

ClinicalTrials.gov NCT05914610

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

AI 简述这是一项III期试验，研究Envolimab联合Fruquintinib和SOX对比SOX用于晚期胃癌转化治疗。

?

适用疾病: Gastric Cancer
干预: Envolimab，Fruquintinib，Oxaliplatin，Tegafur
地点: 未列出
申办方: Fujian Medical University

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06093425

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

AI 简述这是一项III期试验，研究Osemitamab联合Pembrolizumab和化疗用于晚期或转移性胃癌/胃食管结合部腺癌。

?

适用疾病: Gastric Cancer；Gastroesophageal-junction Cancer；Advanced Cancer
干预: Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil，Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil
地点: 未列出
申办方: Suzhou Transcenta Therapeutics Co., Ltd.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06411171

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

AI 简述这是一项III期试验，研究Pembrolizumab联合FLOT化疗用于胃食管交界处癌。

?

适用疾病: Gastroesophageal Junction Cancer
干预: Pembrolizumab plus chemotherapy (FLOT)
地点: 未列出
申办方: xiaohua li

即将招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT06977061

Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

AI 简述这是一项II/III期试验，研究呋喹替尼联合信迪利单抗和立体定向放疗用于胃癌或胃食管结合部腺癌。

?

适用疾病: Gastric Neoplasm
干预: Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy
地点: 未列出
申办方: Queling Liu

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07673887

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

AI 简述这是一项III期试验，研究ASP2138联合化疗和帕博利珠单抗用于胃腺癌。

?

适用疾病: Gastric Adenocarcinoma；Gastroesophageal Junction (GEJ) Adenocarcinoma
干预: ASP2138，Pembrolizumab，Oxaliplatin，Capecitabine
地点: 未列出
申办方: Astellas Pharma Global Development, Inc.

暂时不招募 Phase 1

NCI NCT02366819 / NCI-2014-02574

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of gFOLFIRINOX in Treating Patients with Locally Advanced Gastroesophageal or Stomach Cancer

AI 简述这是一项I期试验，研究基因指导下的伊立替康剂量调整用于局部晚期食管胃结合部腺癌或胃癌。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

暂时不招募 Phase 2

NCI NCT03776487 / NCI-2018-02344

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients with Resectable Gastric Cancer

AI 简述这是一项II期试验，研究Nivolumab、Ipilimumab和放化疗用于可切除胃癌。

?

适用疾病: Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT04650451 / NCI-2021-00052

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

AI 简述这是一项I期试验，研究HER2靶向双开关CAR-T细胞（BPX-603）用于HER2阳性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Bellicum Pharmaceuticals

暂时不招募 Phase 1

NCI NCT04714983 / NCI-2021-00608

DNX-2440 for Resectable Colorectal Liver Metastasis

AI 简述这是一项I期试验，研究DNX-2440用于可切除的结直肠癌肝转移，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: DNAtrix, Inc.

暂时不招募 Phase 1

NCI NCT05159050 / NCI-2022-03835

Paclitaxel-Loaded Tumor Penetrating Microparticles for the Treatment of Peritoneal Carcinomatosis

AI 简述这是一项I期试验，研究紫杉醇负载肿瘤穿透微粒用于腹膜癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Gastric Carcinoma；Metastatic Ovarian Carcinoma
干预: 未列出
地点: United States
申办方: University of Iowa/Holden Comprehensive Cancer Center

暂时不招募 Phase 1

NCI NCT05400122 / NCI-2022-07858

Universal Donor Natural Killer Cells in Combination with Aldesleukin and Vactosertib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal, Gastric and Esophageal Cancers and Relapsed or Refractory Hematologic Cancers

AI 简述这是一项I期试验，研究通用供者NK细胞联合Aldesleukin和Vactosertib用于局部晚期或转移性结直肠癌、胃癌、食管癌及血液肿瘤。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Case Comprehensive Cancer Center

暂时不招募 Phase 1

NCI NCT05958199 / NCI-2023-06569

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

AI 简述这是一项I期试验，研究NPX267用于表达HHLA2/B7-H7的实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: NextPoint Therapeutics, Inc.

暂时不招募 Phase 2

NCI NCT06044311 / NCI-2023-10645

Vactosertib for the Treatment of Patients who are Undergoing Standard of Care Chemoradiation for Locally Advanced Esophageal Cancer

AI 简述这是一项II期试验，研究Vactosertib联合标准放化疗用于局部晚期食管癌。在美国开展。

?

适用疾病: Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Case Comprehensive Cancer Center

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT05978882

Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4)

AI 简述这是一项可行性研究，评估荧光引导下前哨淋巴结导航手术用于早期胃癌。

?

适用疾病: Early Gastric Cancer
干预: Laparoscopic sentinel navigation surgery using fluorescence
地点: South Korea
申办方: National Cancer Center, Korea

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT06892392

Application of Indocyanine Green Tracer in D2 Lymphadenectomy of Locally Advanced Gastric Cancer

AI 简述这是一项试验，在西班牙应用吲哚青绿示踪剂用于局部晚期胃癌D2淋巴结清扫术。

?

适用疾病: GASTRIC CANCER；Indocyanine Green (ICG)；Lymph Node Excision
干预: ICG administration
地点: Spain
申办方: Hospital of Navarra

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT07295002

Sentinel Node Resection With or Without LECS After Noncurative ESD for EGC

AI 简述这是一项试验，在瑞典开展，比较前哨淋巴结切除联合或不联合腹腔镜内镜合作手术用于早期胃癌内镜切除后的治疗。

?

适用疾病: Early Gastric Cancer
干预: ICG-guided lymphadenectomy，Laparoscopic and endoscopic cooperative surgery (LECS)
地点: Sweden
申办方: Region Stockholm

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT07408999

Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer

AI 简述这是一项试验，比较全微创与杂交微创食管切除术用于食管癌，在法国开展。

?

适用疾病: Resecable Esophageal or Gastroesophageal Junction Cancer
干预: Totally Minimally Invasive Esophagectomy (TMIE)，Hybrid Esophagectomy (HE)
地点: France
申办方: University Hospital, Lille

即将招募阶段未标明药物手术/操作

ClinicalTrials.gov NCT07452471

Comparison of the Postoperative Analgesic Effects of the Temperature-responsive Gel Mixed With Local Anesthetics Application and Ultrasound-guided Transversus Abdominis Plane Block in Patients Undergoing Laparoscopic Gastrectomy

AI 简述这是一项试验，比较温敏凝胶混合局麻药与超声引导腹横肌平面阻滞用于腹腔镜胃切除术术后镇痛。

?

适用疾病: Gastric Cancer；Postoperative Pain
干预: Ultrasound-guided Transversus Abdominis Plane (TAP) Block，Ropivacaine-Poloxamer 407 Hydrogel (Welpass®)
地点: South Korea
申办方: Gyeong-Jo Byeon, MD, PhD

即将招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov NCT07594548

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

AI 简述这是一项I期试验，研究Futibatinib联合紫杉醇和雷莫西尤单抗用于晚期胃癌、食管胃结合部癌或食管腺癌。

?

适用疾病: Clinical Stage II Esophageal Adenocarcinoma AJCC v8；Clinical Stage III Esophageal Adenocarcinoma AJCC v8；Clinical Stage III Gastric Cancer AJCC v8
干预: Biospecimen Collection，Computed Tomography，Futibatinib，Magnetic Resonance Imaging
地点: United States
申办方: Northwestern University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06094868

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

AI 简述这是一项II期试验，研究Fruquintinib联合Sintilimab和XELOX方案用于晚期胃癌。

?

适用疾病: Gastric Cancer
干预: Fruquintinib
地点: 未列出
申办方: Second Affiliated Hospital of Nanchang University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06238167

Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

AI 简述这是一项2期试验，研究替雷利珠单抗联合化疗用于老年胃癌术后辅助治疗。

?

适用疾病: Gastric Cancer
干预: Tislelizumab，S-1 therapy，low dose SOX therapy
地点: 未列出
申办方: First Affiliated Hospital of Wenzhou Medical University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06439550

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

AI 简述这是一项II期试验，研究斯鲁利单抗联合曲妥珠单抗和SOX方案用于HER2阳性胃癌辅助治疗。

?

适用疾病: HER2-positive Gastric Cancer
干预: Serplulimab，Trastuzumab，Oxaliplatin + Tegafur
地点: 未列出
申办方: The First Affiliated Hospital of Zhengzhou University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06459921

Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer

AI 简述这是一项II期试验，比较SOX+Sintilimab与FLOT+Sintilimab用于局部晚期胃癌新辅助治疗。

?

适用疾病: Neoadjuvant Chemotherapy；Sintilimab；Locally Advanced Gastric Cancer
干预: SOX+Sintilimab，FLOT+Sintilimab
地点: 未列出
申办方: Xijing Hospital

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT06511609

The Anti-reflux Effect of Double-flap Technique in Laparoscopic Proximal Gastrectomy.

AI 简述这是一项试验，研究双瓣技术在腹腔镜近端胃切除术中的抗反流效果用于近端早期胃癌。

?

适用疾病: Proximal Early Gastric Cancer
干预: double-flap technique（DFT）; double-tract reconstruction(DTR),
地点: 未列出
申办方: Changzhi People's Hospital Affiliated to Changzhi Medical College

即将招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT06525714

Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer

AI 简述这是一项早期I期试验，研究根治术后腹腔热灌注化疗（HIPEC）用于局部晚期胃癌的长期生存。

?

适用疾病: Gastric Cancer；Survival Rate
干预: cisplatin oxaliplatin tegafur
地点: 未列出
申办方: The First Hospital of Jilin University

即将招募阶段未标明药物手术/操作

ClinicalTrials.gov NCT06603974

The Efficacy and Safety of Benmelstobart for GC/EGC

AI 简述这是一项试验，研究Benmelstobart联合替吉奥和奥沙利铂用于胃癌。

?

适用疾病: Gastric Cancer
干预: surgery，Benmelstobart，tegafur，oxaliplatin
地点: 未列出
申办方: Xijing Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06697366

Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

AI 简述这是一项2期试验，研究脂质体伊立替康联合信迪利单抗用于进展期胃癌的二线治疗。

?

适用疾病: Gastric Cancer
干预: Irinotecan liposome injection Ⅱ，Sintilimab
地点: 未列出
申办方: Ruijin Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06764251

Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma

AI 简述这是一项II期试验，研究Tislelizumab联合SOX方案用于局部晚期胃癌/胃食管结合部腺癌。

?

适用疾病: Gastric/Gastroesophageal Junction Adenocarcinoma
干预: Tislelizumab + SOX
地点: 未列出
申办方: Liaoning Cancer Hospital & Institute

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT06934824

Clinical Study of Double-Endoscopic Combined With Minimally Invasive Treatment for Early Gastric Cancer at Clinical Stage T1b

AI 简述这是一项临床研究，双镜联合微创治疗用于临床T1b期早期胃癌。

?

适用疾病: Gastric Cancer Patients Undergoing Minimally Invasive Gastrectomy
干预: Sixty patients with early gastric cancer in stage T1bN0-1M0 were divided into Group A-N0 and Group B-N + according to the presence or absence of lymph node metastasis. When the enrolled patients und
地点: 未列出
申办方: Hebei Medical University

即将招募 Phase 2 药物其他

ClinicalTrials.gov NCT06942663

Randomized Phase II Trial Evaluating DFS in The Absence of an Adjuvant Component of Perioperative Chemotherapy in Patients With Gastric Cancer

AI 简述这是一项2期随机试验，评估胃癌患者围手术期化疗后观察对比辅助化疗的无病生存期。

?

适用疾病: Gastric Cancer
干预: Surveillance，Adjuvant Chemotherapy
地点: 未列出
申办方: Nizhny Novgorod Regional Clinical Oncology Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06942767

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

AI 简述这是一项2期试验，研究QLS31905、QL2107和化疗用于CLDN18.2阳性胃腺癌。

?

适用疾病: Gastric Adenocarcinoma；Gastroesophageal Junction Adenocarcinoma
干预: QLS31905 for Injection，QL2107 Injection，Oxaliplatin Injection，Capecitabine Tablets
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07085273

Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer

AI 简述这是一项II期试验，研究伊立替康脂质体联合化疗用于胃癌新辅助治疗。

?

适用疾病: Gastric Cancer
干预: Irinotecan Liposomal
地点: 未列出
申办方: The First Affiliated Hospital of Zhengzhou University

即将招募阶段未标明药物

ClinicalTrials.gov NCT07092449

Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma

AI 简述这是一项试验，研究Pucotenlimab联合化疗用于局部晚期胃食管交界处癌。

?

适用疾病: Gastroesophageal Junction；Gastric / Gastroesophageal Junction Adenocarcinoma；Neoadjuvant Chemoimmunotherapy
干预: Neoadjuvant chemo-immunotherapy
地点: 未列出
申办方: Tang-Du Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07126561

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

AI 简述这是一项II期试验，研究Trastuzumab Deruxtecan用于HER2阳性新诊断转移性食管、胃、胃食管结合部癌。

?

适用疾病: HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
干预: Trastuzumab Deruxtecan
地点: 未列出
申办方: University of Chicago

即将招募 Phase 4 药物

ClinicalTrials.gov NCT07132528

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

AI 简述这是一项IV期试验，比较化疗联合或不联合免疫治疗用于可切除胃或胃食管结合部腺癌根治术后的辅助治疗。

?

适用疾病: Gastric / Gastroesophageal Junction Adenocarcinoma
干预: SOX plus PD-1 inhibitor，SOX Chemotherapy
地点: 未列出
申办方: Liaoning Cancer Hospital & Institute

即将招募 Phase 4 药物

ClinicalTrials.gov NCT07149181

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery

AI 简述这是一项4期试验，比较化疗联合或不联合免疫治疗用于可切除胃癌术后辅助治疗。

?

适用疾病: Gastric / Gastroesophageal Junction Adenocarcinoma
干预: SOX plus PD-1 inhibitor，SOX Chemotherapy
地点: 未列出
申办方: Liaoning Cancer Hospital & Institute

即将招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov NCT07243938

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

AI 简述这是一项2期篮式试验，研究Zanidatamab联合Tislelizumab用于HER2阳性胃肠道肿瘤。

?

适用疾病: Locally Advanced Rectal Cancer (LARC)；Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma；Metastatic Colorectal Cancer (mCRC)
干预: short-course radiotherapy，Zanidatamab，Tisleizumab(BGB-A317)，Capecitabine
地点: 未列出
申办方: Tao Zhang

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07252661

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究ACC-1898用于晚期实体瘤。

?

适用疾病: Hepatocellular Carcinoma；Renal Cell Carcinoma；Thyroid Carcinoma, Medullary
干预: ACC-1898
地点: 未列出
申办方: AccSalus Biosciences, Inc.

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT07260461

The Efficacy and Safety of Laparoscopic Proximal Gastrectomy With LPG-tbROSF Versus LTG for Localized Proximal Gastric Cancer.

AI 简述这是一项试验，比较腹腔镜近端胃切除术（LPG-tbROSF）与全胃切除术用于局部近端胃癌。

?

适用疾病: Stomach Neoplasms；Adenocarcinoma - Gastroesophageal Junction (GEJ)；Gastroesophageal Junction Cancer
干预: Laparoscopic Proximal Gastrectomy with Tubular Stomach-Based Right-Opening Single Flap Valvuloplasty (LPG-tbROSF)
地点: 未列出
申办方: First Affiliated Hospital of Wenzhou Medical University

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07358884

First in Human Study of QLS5316 in Solid Tumors

AI 简述这是一项I期试验，研究QLS5316用于多种实体瘤。

?

适用疾病: Solid Tumors；Colorectal Cancer；Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
干预: QLS5316
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

即将招募阶段未标明药物

ClinicalTrials.gov NCT07371871

A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer

AI 简述这是一项试验，研究TAS-102联合阿帕替尼用于晚期胃癌三线治疗。

?

适用疾病: Advanced Gastric Cancer
干预: Trifluridine/Tipiracil (TAS-102) combined with Apatinib
地点: 未列出
申办方: Anhui Provincial Cancer Hospital

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07453394

QLS5132 Combination Therapy in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究QLS5132联合治疗用于多种晚期实体瘤。

?

适用疾病: Gastric Cancer (GC)；Non-small Cell Lung Cancer (NSCLC)；Endometrial Cancer
干预: QLS5132; Bevacizumab，QLS5132; Platinum; Bevacizumab，QLS5132; Olaparib; Bevacizumab，QLS5132; QL1706; QL2107
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

即将招募 Phase 4 药物

ClinicalTrials.gov NCT07502027

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

AI 简述这是一项IV期试验，研究Iparomlimab和Tuvonralimab联合SOX和放疗用于一线HER2阴性胃癌或胃食管结合部腺癌。

?

适用疾病: Gastric Cancer (Diagnosis)；Gastric Cancer (GC)；Gastroesophageal Junction Adenocarcinoma
干预: Iparomlimab and Tuvonralimab (QL1706)
地点: 未列出
申办方: Huazhong University of Science and Technology

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07631884

Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor

AI 简述这是一项II期试验，研究Trastuzumab Rezetecan用于HER2表达晚期实体瘤。

?

适用疾病: Solid Tumors；Neoplasms (Cancer / Tumors)；Advanced Malignant Solid Neoplasm
干预: Trastuzumab Rezetecan
地点: 未列出
申办方: Haihua Yuan

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07638631

Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer

AI 简述这是一项II期试验，研究Ipilimumab联合信迪利单抗和改良XELOX用于不可切除局部晚期胃癌。

?

适用疾病: Locally Advanced Gastric Cancer
干预: Ipilimumab injection N01，Sintilimab，Modified (60% standard dose) XELOX
地点: 未列出
申办方: Chen Lizhu

即将招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT06748872

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

AI 简述这是一项I期试验，研究MDG1015用于上皮性卵巢癌、胃食管交界癌、软组织肉瘤等，在美国开展。

?

适用疾病: Epithelial Ovarian Cancer；Gastro-esophageal Junction Cancer；Soft Tissue Sarcoma (STS)
干预: Lymphodepletion，TCR-T cells (MDG1015)
地点: United States
申办方: Medigene AG

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07144657

Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma

AI 简述这是一项II期试验，在台湾研究抗生素治疗用于早期HP阴性胃MALT淋巴瘤。

?

适用疾病: MALT Lymphoma of Stomach
干预: Esomeprazole, Bismuth tripotassium dicitrate, Tetracycline, and Metronidazole
地点: Taiwan
申办方: National Taiwan University Hospital

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT05095467

HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction

AI 简述这是一项II期试验，研究HIPEC-AS用于胃癌或食管胃结合部腹膜转移患者。

?

适用疾病: Stomach Neoplasms；Peritoneal Metastases
干预: HIPEC，Paclitaxel-albumin，Tegafur-gimeracil-oteracil potassium，Surgery+HIPEC
地点: 未列出
申办方: Xuefei.Wang

术语	中文意思	对找临床试验有什么用
胃癌 / Gastric cancer	发生在胃部的恶性肿瘤。海外记录中也常写 stomach cancer。	可以同时尝试 gastric cancer 和 stomach cancer。
胃食管结合部癌 / GEJ cancer	发生在胃和食管交界区域的癌症，部分试验会和胃癌一起招募。	搜索时可加入 gastroesophageal junction 或 GEJ。
HER2-positive	部分胃癌或 GEJ 癌存在 HER2 高表达或扩增。	可以找 HER2 靶向药、ADC、联合治疗相关试验。
CLDN18.2	Claudin 18.2 是胃癌中常见研究靶点之一。	可以找 CLDN18.2 antibody、CAR-T、ADC 等相关试验。
PD-L1	和免疫治疗相关的生物标志物，常用 CPS 表达。	免疫治疗试验可能要求 PD-L1 CPS 或按其分层。
MSI-H / dMMR	提示微卫星高度不稳定或错配修复异常。	可以找免疫治疗相关试验。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

胃癌

当前同步到的治疗类试验